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Posttranslational histone modifications are recognized as important regulators of 
gene expression. One of them, the monoubiquitination of lysine 120 of histone H2B 
(H2Bub1), has diverse functions and is involved in gene transcription as well as in 
controlling mRNA processing, DNA repair and DNA replication. Notably, H2Bub1 is 
associated with actively transcribed genes and has been linked to ongoing 
transcription. The misregulation of H2Bub1-modifying machinery has been observed 
to be tightly linked with different types of cancer. In the course of this study we 
clarified aspects of the regulation of the H2B ubiquitinating enzymes and presented 
data which support the hypothesis that the RNF20/RNF40 complex has a tumor-
suppressor function probably through its regulation of H2Bub1. Moreover, we present 
data that demonstrate a rapid and massive loss of H2Bub1 following various cell 
stresses. Elucidating the mechanism and signaling pathways which control this 
process was one major goal of this study. It was demonstrated that H2Bub1 depletion 
could be rescued through knockdown of various subunits of the deubiquitinating 
module of the SAGA complex. ChIP-seq analyses obtained in this study 
demonstrated that H2Bub1 does not cover the entire transcribed region uniformly nor 
do the average ChIP signal profiles of H2Bub1 correlate with gene expression. 
However, the deubiquitination and therefore probably the new ubiquitination do 
correlate with gene activity. 
Collectively, these studies have uncovered important mechanisms regulating H2Bub1 
and may serve as a basis for developing a more solid knowledge of stress-induced 
H2B deubiquitination and the role of H2B monoubiquitination during tumorigenesis 
and metastasis. The data provide a potential role of H2Bub1 in epigenetic-based 





1.1 Chromatin structure 
Eukaryotic organisms have established ways of packaging DNA into chromatin since 
2 m of genomic DNA needs to fit into a nucleus of just 10 m diameter and be 
accessible at the same time (Felsenfeld and Groudine, 2003). 
Chromatin is a complex of DNA, histones and other proteins that form the 
chromosome. The basic building block of chromatin is the nucleosome which 
consists of DNA and histones. The typical nucleosome contains an octamer of 
histones with two copies of histone H3/H4 heterodimers which form a stable tetramer 
as well as two flanking copies of histones H2A/H2B heterodimers (Kornberg, 1974). 
Around the histone octamer 147 base pairs of DNA are wrapped (Luger et al., 1997). 
The H1 histone is not part of the core nucleosome, but binds to linker DNA (10-80 bp 
long, depending on species and tissue) located between adjacent nucleosome which 
promotes in concert with other non-histone proteins the formation of the higher-order 
chromatin structures (Allan et al., 1981; Thomas, 1999). 
Chromatin is compacted into several higher order structures starting with the 
formation of the linear 11 nm fiber-like structure in which nucleosomes are arranged 
in a beads on a string fashion separated by linker DNA (Fig. 1) (Kornberg, 1974). To 
increase the condensation, chromatin is packed into a thicker fiber with 30 nm 
diameter (Marsden and Laemmli, 1979). The 30 nm fiber produces a net compaction 
of roughly 50-fold. The in vivo existence of the 30 nm fiber has been put into question 
and little is known about how these fibers are further packed within the nucleus to 
form the highest-order structures (Felsenfeld and Groudine, 2003). 
Formally, cellular chromatin can be divided into two major states: heterochromatin 
and euchromatin. Heterochromatin is by definition highly condensed, contains only 
few genes, and is mostly transcriptionally inactive. In contrast, euchromatin contains 
a high density of genes and can either be actively transcribed or repressed (Grewal 
and Elgin, 2007; Henikoff, 2000; Richards and Elgin, 2002). However, based on 




into more different types of chromatin by structure, composition, epigenetic make-up 
and function (Bickmore and van Steensel, 2013). 
 
 
Fig. 1: Hierarchy of chromatin structure. DNA is wrapped around a histone octane to form a 
nucleosome. Nucleosomes connected by stretches of linker DNA in the least condensed structures 
are folded into a fiber-like structure of about 11 nm in diameter and when further compacted form a 
fiber with a diameter of about 30 nm. The 30-nm fibers can be further compacted into higher-order 
structures (taken from Alberts et al., 2002).  
 
1.2 Histone modifications 
In the cell nucleus, chromatin exists in many configurations and undergoes dynamic 
structural changes that play key roles in genome templated processes. The functional 
state of chromatin is partially regulated through posttranslational modifications 




transcriptional regulation, nuclear architecture, cell differentiation and development 
(Jenuwein and Allis, 2001).  
Histone proteins consist of a core domain and C- and N-terminal tails. The globular 
domain is formed by three helices and is required for the nucleosome formation 
(Luger et al., 1997). The so-called ‘histone tails’ protrude away from the DNA and 
thus remain at the surface of the nucleosome. This makes them accessible for 
enzymes and allows them to go undergo different PTMs (Jenuwein and Allis, 2001; 
Luger et al., 1997; Rando and Winston, 2012). The flexible positively charged N-
termini were found to mediate internucleosomal contacts (Luger et al., 1997) and can 
change their interaction when the chromatin fiber undergoes folding or compaction 
(Wolffe and Hayes, 1999). Numerous types of histone modifications exist (Fig. 2). 
The most studied among them are phosphorylation of serine and threonine residues, 
methylation of lysine and arginine and acetylation of lysine. Poorer understood  
modifications include ubiquitination and sumoylation of lysine and ADP-ribosylation of 
glutamic acid, where larger peptides or entire proteins are added (Fischle et al., 
2003; Imhof, 2003; Johnsen, 2012a; Osley, 2004). The histone posttranslational 
modifications can influence chromatin in different manners and are therefore 
recognized as important regulators of protein function and stability and protein-





Fig. 2: Main posttranslational histone modifications. Histone N-terminal tails are post-
translationally modified and certain combinations of histone modifications appear to generate a 
‘histone code’ defining the chromatin state. The number under each amino acid indicates its position in 
the sequence of histones in human cells (modified from Kato et al., 2010). 
 
1.2.1 “Histone code” 
The high diversity of histone modifications, as well as high number of residues that 
can be modified and the correlation of individual modifications with various nuclear 
processes led to the hypothesis that specific combinations of histone modifications 
provide a ‘histone code’ (Strahl and Allis, 2000; Turner, 1993, 2000). Histone 
modifications can influence each other in a synergistic or antagonistic way leading to 
specific imprint patterns (Jenuwein and Allis, 2001). Some histone modifications are 
associated with transcriptional activation, others with transcriptional 
repression/silencing. For example, histone acetylation and deacetylation is studied in 
much detail and the status of this PTM is regulated enzymatically by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) (Strahl and Allis, 





called ‘trans-histone’ regulatory pathway (Fischle et al., 2003). However, the 
biological outputs of the histone code hypothesis are more difficult to interpret than 
initially hypothesized. To predict the outcomes of histone modifications much more 
knowledge about the so-called epigenetic writers, readers, erasers and associated 
non-histone proteins which affect cellular function is needed. In the context of 
tumorigenesis it is hypothesized that alteration in the balance between epigenetic ‘on’ 
versus ‘off’ chromatin states lead to inappropriate expression or silencing of gene 
programs (Chi et al., 2010). 
1.2.2 Misregulation of histone modifications 
Epigenetic imbalances, caused by deregulation of factors that mediate the deposition 
or removal of histone modifications are associated with the initiation, progression and 
metastasis of human cancer (Chi et al., 2010). 
Histone H3 can be methylated at different sites and these modification can exist in 
different combinations which exhibits distinct distribution patterns resulting in different 
functional consequences for the corresponding genes in the mammalian 
chromosome (Barski et al., 2007). For instance, H3K4 trimethylation (H3K4me3) is 
strongly connected to transcriptional activation, whereas H3K27 trimethylation 
(H3K27me3) is frequently associated with gene silencing (Barski et al., 2007; 
Bernstein et al., 2006a; Mikkelsen et al., 2007). Distribution patterns of for example 
H3K4 and H3K27 histone modifications underlie the variety of cellular states for 
pluripotency and lineage differentiation. Active and repressive histone modifications 
can co-exist and this bivalent chromatin state provide a mechanism to maintain 
chromatin plasticity and is important for early stages of embryogenesis and 
development (Bernstein et al., 2006b; Mikkelsen et al., 2007). Epigenetic aberrations 
may be involved in tumor development since several reports suggest that the global 
loss of trimethylated H3 and H4 is a hallmark of tumor cells (Fraga et al., 2005).  
Several reports demonstrated that both overexpression and inactivation of the H3K79 
methyltransferase Dot1 lead to a loss of telomeric silencing (van Leeuwen et al., 
2002; Ng et al., 2002a; Park et al., 2010). Dot1-dependent H3K79 methylation has 
also been shown to be associated with restricting the Sir proteins at heterochromatic 




checkpoint (San-Segundo and Roeder, 2000) and DNA damage checkpoint of Rad9 
in yeast (Wysocki et al., 2005). Further, misregulation of H3K79 methylation 
contributes to leukemogenesis in humans (Okada et al., 2005). DOT1L and H3K79 
methylation are associated with transcriptional activation (Steger et al., 2008), thus 
providing a possible explanation for aberrant transcriptional activation found in many 
MLL gene fusion induced leukemia (Chi et al., 2010). 
Analysis of expression of the enzyme EZH2 (Enhancer of zeste homolog 2), a 
H3K27-specific methyltransferase provided another connection between 
misregulated histone methylation marks and oncogenesis. EZH2 is frequently 
overexpressed in several solid tumors including prostate, breast, colon, skin and lung 
cancers (Bracken and Helin, 2009; Simon and Lange, 2008). RNA interference-
mediated suppression of EZH2 decreases tumor growth in breast and prostate tumor 
xenograft models (Gonzalez et al., 2009; Yu et al., 2007). In addition to its well-
known function in epigenetic gene silencing, EZH2 is implicated in the regulation of 
cell differentiation in several tissue-specific stem cells (Chen et al., 2012). H3K27 di- 
and tri-methylation are specific PcG (Polycomb group) targets (Schwartz and Pirrotta, 
2008). Both PRC1 (Polycomb repressive complex 1) and PCR2 catalyze repressive 
histone posttranslational modifications. While PRC1 catalyzes the monoubiquitination 
of histone H2A at lysine 119, PRC2 is involved in the methylation of H3K27 
(Margueron and Reinberg, 2011) via its histone methyltransferase EZH2 (Neri et al., 
2012). Silencing of developmental regulator genes by the two major PRCs can 
influence pluripotency of stem cells (Richly et al., 2010; Schwartz and Pirrotta, 2008). 
1.2.3 Histone monoubiquitination 
Ubiquitination of histone molecules was found for histones H2A, H2B, H3, H4, H2A.Z, 
macroH2A and H1. In most cases only a single ubiquitin molecule is attached to 
histones, which is not sufficient for targeting via the 26S proteasome (Kinyamu et al., 
2005; Osley, 2006; Zhang, 2003).  
The first-reported ubiquitination substrate was histone H2A (Goldknopf and Busch, 
1977). It has been shown that H2Aub1 is enriched in gene loci with low transcription 
activity and is carried out by PRC1. In mammalian cells the PRC1 complex contains 




RING1B mediates H2Aub1 and was identified to bind PRC2 in the absence of PRC1 
(Ku et al., 2008). Several studies demonstrated the requirement of PRC1 for stabile 
silencing of the gene and additional compaction (Eskeland et al., 2010; Francis et al., 
2004; Stock et al., 2007). H2Aub1 is associated with the repression of developmental 
genes such as the Hox gene cluster (Osley, 2006). In addition, H2Aub1 not only 
plays a role in transcription, it has been shown to be involved in DNA repair also 
(Bergink et al., 2006; Dérijard et al., 1995; Doil et al., 2009; Kolas et al., 2007; 
Mailand et al., 2007; Marteijn et al., 2009). 
1.2.3.1 Histone H2Bub1 
Monoubiquitination of histone H2B (H2Bub1) is widely distributed within eukaryotes 
but is less abundant (1-2% of total H2B) in contrast to H2Aub1 (Osley, 2006; Zhang, 
2003). The ubiquitination of H2B occurs in a three step enzymatic process 
(Hochstrasser, 1996). First of all, ubiquitin gets activated by an ubiquitin activating 
enzyme (E1). Then, it is conjugated to a cysteine residue of an ubiquitin conjugating 
enzyme (E2) and finally transferred to a target lysine residue via an ubiquitin-ligase 
(E3) (Weake and Workman, 2008). Monoubiquitination is involved in gene 
transcription, DNA repair and DNA replication whereas polyubiquitination supports 
degradation (Sun and Chen, 2004). Polyubiquitination chains are formed by 
conjugating ubiquitin residues and the emerging linear polyubiquitination chains can 
be linked by amide bonds and thus, a number of different polyubiquitination linkages 
exist in cells (Kirisako et al., 2006). Different linkages seem to have distinct functions. 
For example, while polyubiquitination linked through K48 targets signals for 
degradation via the 26S proteasome (Glickman and Ciechanover, 2002), 
polyubiquitination linked through K63 recruits different binding partners and is 
involved in kinase activation (Deng et al., 2000), protein synthesis (Spence et al., 
2000), DNA repair (Hoege et al., 2002; Hofmann and Pickart, 1999) and 
chromosome segregation (Vong et al., 2005). 
In humans H2Bub1 was initially found preferentially in the transcribed region of highly 
expressed genes and at promoter regions of some genes (Minsky et al., 2008). In 
yeast H2Bub1 is required for the re-assembly of nucleosomes during elongation 




yeast, H2Bub1 was suggested to be linked to transcriptional elongation (Fleming et 
al., 2008; Minsky et al., 2008). 
Ubiquitination of H2B was found at K123 in yeast and at K120 in other eukaryotes. 
The E2 enzyme for H2Bub1 in yeast was shown to be radiation-sensitive mutant 
protein 6 (Rad6) and the interacting E3 ligase was identified to be the RING finger 
protein called brefeldin A sensitive protein 1 (Bre1) (Hwang et al., 2003; Robzyk et 
al., 2000; Wood et al., 2003). Based on sequence alignment two homologs for the 
yeast Rad6 protein have been found in humans called UBE2A and UBE2B (Koken et 
al., 1991). A recent study could clearly show that UBE2A is the cognate E2 of the 
BRE1 complex and therefore responsible for the H2B monoubiquitination in human 
cells. Rad6/UBE2A/UBE2B represents a multifunctional E2 enzyme with several 
cellular substrates. These are specifically targeted via the interactions with different 
E3 ligases. The yeast ligase Bre1 is a RING-domain ubiquitin ligase which does not 
possess intrinsic enzymatic activity. Bre1 is an important co-factor for Rad6-mediated 
ubiquitination because it is required for the recruitment of Rad6 to promoters and its 
association with the elongating RNA Polymerase II (RNAPII) (Henry et al., 2003; 
Wood et al., 2003). The human orthologs of Bre1 RNF20 and RNF40, form an 
obligatory heterodimer in vivo and are both required for maintaining H2Bub1 levels in 
human cells (Chernikova et al., 2012; Kari et al., 2011; Karpiuk et al., 2012; 
Pirngruber et al., 2009a). The stability of each partner is dependent upon the 
presence of the other and depletion of either component results in a remarkable 
decrease in the other as well (Kim et al., 2009; Pavri et al., 2006; Zhu et al., 2005). It 
has been reported that RNF20, probably through H2Bub1, activates or suppresses 
distinct gene classes. The sum of these effects on growth promoting and growth 
restrictive pathways, as well as RNF20-related alterations in human cancer, suggest 
a key function of RNF20 as a tumor suppressor (Shema et al., 2008). Conflicting 
studies have left the role of RNF40 in maintaining global H2Bub1 levels and 




1.3 Functional role of H2B monoubiquitination 
1.3.1 H2Bub1 and transcription 
The link between H2B monoubiquitination and transcription is complex. H2B 
ubiquitination has been implicated in transcriptional silencing in yeast (Briggs et al., 
2002; Mutiu et al., 2007; Sun and Allis, 2002) and is suggested to have a positive 
role in transcriptional initiation and elongation (Henry et al., 2003; Shukla et al., 2006; 
Wyce et al., 2007; Xiao et al., 2005b). Gene-specific as well as genome-wide studies 
have revealed that H2Bub1 is associated with transcriptionally active DNA and 
appears to occur primarily co-transcriptionally (Henry et al., 2003; Minsky et al., 2008; 
Tanny et al., 2007; Xiao et al., 2005a). Pavri et al (2006) performed in vitro 
transcription elongation assays to confirm a role for H2Bub1 in facilitating elongation 
by RNA polymerase II. Importantly Kim et al. (2009) showed that ongoing 
transcription is necessary for efficient H2B ubiquitination. 
RNA polymerase II carboxyl-terminal domain (CTD) is the largest subunit of 
eukaryotic RNAPII that contains a conserved 52 repeated heptapeptide in humans 
(Egloff and Murphy, 2008). Ser5 is phosphorylated by cyclin-dependent kinase 7 
(CDK7) and Ser2 is phosphorylated by cyclin-dependent kinase 9 (CDK9). While P-
Ser5 is associated with mRNA capping and transcriptional initiation, P-Ser2 is 
involved in elongation, splicing and mRNA processing (Egloff and Murphy, 2008). 
CDK9 induces the elongation by phosphorylating negative elongation factor-E 
(NELF-E) and suppressor of Ty homologue 5 (SUPT5H) (Fujinaga et al., 2004; 
Yamada et al., 2006; Zhou et al., 2009). This hypothesis was substantiated since 
inhibition or depletion of CDK9 led to a global decrease in H2Bub1 levels while upon 
CDK9 overexpression H2Bub1 is increased (Karpiuk et al., 2012; Pirngruber et al., 
2009a; Sans¢ et al., 2012). 
A direct connection between H2Bub1 and RNAPII CTD Ser2 phosphorylation was 
suggested since they have a similar pattern of localization on the active p21 gene 
(Gomes et al., 2006; Minsky et al., 2008). The identification of WW domain-
containing adaptor with coiled-coil protein (WAC) as part of the RNF20/RNF40 




directly with phosphorylated Ser2 and recruits the RNF20/RNF40 complex to the 
chromatin enabling H2B monoubiquitination (Fig. 3). 
These observations show H2Bub1 as a histone mark that is coupled to RNAPII 
transcriptional elongation in both yeast and humans. 
 
 
Fig. 3: H2Bub1 regulation via the CDK9-WAC-RNF20/RNF40 axis. (from Johnsen, 2012). CDK9 
phosphorylates Ser2 of RNAPII CTD. WAC acts as an adaptor protein, binds to P-Ser2 and promotes 
recruitment of the RNF20/RNF40 complex and UBE2A to the activated gene. UBE2A is 
phosphorylated by CDK9 and becomes activated. Monoubiquitinated H2B leads to promotion of 
elongation and is then removed either by active deubiquitination via USP22 or by histone exchange 
via FACT complex. 
 
1.3.2 Cellular functions of the H2Bub1 in yeast 
In yeast H2Bub1 is excluded from heterochromatin and mostly associated with 
actively transcribed genes (Kao et al., 2004). H2B is transiently ubiquitinated at the 
coding region of several highly expressed yeast genes mediated by the activities of 
the ubiquitin-conjugating enzyme Rad6 and the ubiquitin ligase Bre1. Both are 




complex (Henry et al., 2003; Hwang et al., 2003; Kao et al., 2004; Robzyk et al., 
2000; Wood et al., 2003; Xiao et al., 2005b). Interestingly in the absence of H2B 
deubiquitination, transcription of several inducible genes in yeast is reduced 
suggesting that H2Bub1 has to be dynamically regulated (Henry et al., 2003). 
As already mentioned Paf1 is associated with RNAPII as well as with histone 
methyltransferases and recruits the H2Bub1 machinery to the chromatin in yeast (Li 
et al., 2003; Shi et al., 1996; Wood et al., 2003). The Paf1 interaction with FACT 
(facilitates chromatin transcription) histone chaperone complex (Laribee et al., 2007) 
facilitates an increased H2A/H2B heterodimer removal from the core nucleosomes. 
This leads to a more accessible DNA template and hence more efficient 
transcriptional elongation by RNAPII (Belotserkovskaya et al., 2003; Kireeva et al., 
2002).  
Another way by which H2Bub1 facilitates transcription is through interplay with other 
histone modifications. Methylation of lysine 4 in the amino-terminal tail of histone H3 
is mediated by COMPASS1 (complex of proteins associated with Set1), a 
multiprotein complex (Briggs et al., 2001; Krogan et al., 2002; Miller et al., 2001; 
Nagy et al., 2002; Roguev et al., 2001) which is required for telomeric silencing of 
gene expression (Briggs et al., 2001; Krogan et al., 2002). The ubiquitin-conjugating 
enzyme Rad6 is required for methylation of lysine 4 of histone H3 (H3K4me) since 
H2Bub1 serves as recognition signal for Set1/COMPASS recruitment (Dover et al., 
2002).  
In addition to H3K4 methylation, H2Bub1 promotes H3K79 methylation through a so-
called trans-tail mechanism (Briggs et al., 2002; Dover et al., 2002; Ng et al., 2002b; 
Sun and Allis, 2002). H2Bub1 has been shown to recruit the histone 
methyltransferases Set1 and Dot1 to di- and trimethylate H3K4 and H3K79 and 
facilitate histone cross talk in yeast and mammals (Fierz et al., 2011; Kim et al., 2009; 
Lee et al., 2007; Sun and Allis, 2002). 
1.3.3 The role of H2Bub1 in higher eukaryotes 
While the role of H2Bub1 in yeast is well explored, the precise functional role in 
mammalian cells remains largely unknown. H2Bub1 depletion alters the expression 




repression of certain genes suggests that this modification plays a complex role in 
mammalian cellular processes (Shema et al., 2008). 
Whereas H2Bub1 and H3K36me3 in mammalian cells are associated with 
transcribed regions of active genes, H3K4me3 was preferentially found at the 
transcriptional start sites and 5′ ends of genes (Minsky et al., 2008). Similarly to S. 
cerevisiae, H2Bub1 in higher eukaryotes facilitates efficient transcriptional elongation 
through the FACT complex (Pavri et al., 2006; Schwabish and Struhl, 2004). 
Conversely, H2Bub1 could modulate chromatin dynamics by promoting FACT 
function during transcriptional elongation (Fleming et al., 2008; Pavri et al., 2006). 
Structural studies previously showed that H2Bub1 facilitates cancer by providing a 
more ‘open’ chromatin conformation (Fierz et al., 2011). Moreover, the addition of a 
similar, but chemically distinct moiety with different surface charges did not mimic the 
action of H2Bub1. This was shown in yeast, where sumoylation did not have the 
same effects compared to H2Bub1 on transcription (Batta et al., 2011) Thus, the 
decompaction of the chromatin seems to be dependent on the chemical nature of 
ubiquitin (Fierz et al., 2011). 
Furthermore, an additional role for H2Bub1 was shown in the regulation of gene 
expression by interfering with 3’end mRNA processing. Pirngruber et al. (2009) 
showed the requirement of H2Bub1 for correct stem loop-dependent processing of 
histone genes and revealed a new role for CTD phosphorylation in controlling this 
process since H2Bub1 regulation is mediated by CDK9 via a CTD-dependent PAF-
RNF20/RNF40 complex (Pirngruber et al., 2009a). 
Apart from its role in transcription, a substantial amount of evidence has accumulated 
that H2Bub1 also participates in other cellular processes including DNA damage 
signaling and cell cycle checkpoint activation (Chernikova et al., 2012; Kari et al., 
2011; Moyal et al., 2011; Nakamura et al., 2011). The E3 ubiquitin ligases RNF20 
(Matsuoka et al., 2007; Mu et al., 2007) and RNF40 (Mu et al., 2007; Stokes et al., 
2007) were identified as substrates of the ATM and ATR kinases. It is proposed that 
their recruitment upon double strand break (DSB) generation to the DSB-site is 
required for recruitment of the repair machinery (Moyal et al., 2011). A mechanistic 




although studies provide a role for H2Bub1 in the process of homologous 
recombination and non-homologous end joining DNA repair (Moyal et al., 2011; 
Nakamura et al., 2011). An implication of FACT in the exchange of γH2AX/H2B 
dimers was shown in a recent study (Heo et al., 2008) and in addition our group 
proposed the importance of RNF40 activity for proper FACT recruitment to chromatin 
upon DNA damage (Kari et al., 2011). 
1.3.4 Genome-wide distribution of H2Bub1 
In a previous chapter it was mentioned that the dynamic turnover of H2Bub1 is critical 
to both transcription and gene silencing. H2Bub1 regulates chromatin dynamics by 
enhancing nucleosome stability (Chandrasekharan et al., 2009) and disrupting local 
and higher-order chromatin compaction (Fierz et al., 2011). Out of these findings 
H2Bub1 seems to be involved in additional regulatory pathways besides trans-
crosstalk with the methylations of histone H3. To investigate genome-wide properties 
and unique roles of H2Bub1 in cooperation with other histone modifications Minsky et 
al. (2008) generated a highly specific H2Bub1 antibody and performed ChIP-chip and 
ChIP-seq analysis. 
Recently published high-throughput sequencing (ChIP-seq) data for the genome-
wide occupancies of H2Bub1 in human teratocarcinoma NCCIT cells showed that 
H2Bub1 is a 5′-enriched active transcription mark of almost all expressed genes with 
its levels progressively decreasing towards the 3’ region (Jung et al., 2012). 
Furthermore, H2Bub1 was strongly enriched at the exon-intron boundaries of highly 
expressed exons and in contrast H2Bub1 was depleted from non-expressed genes 
and from intergenic regions. H2Bub1 distribution correlates with that of H3K36me3 
and H3K79me2, two marks associated with transcriptional elongation (Jung et al., 
2012). Similar observations were made in Drosophila melanogaster or Arabidopsis 
thaliana using the same antibody that recognizes H2Bub1 in these species 
(Kharchenko et al., 2011; Roudier et al., 2011; Roy et al., 2010). This distribution 
profile is in agreement with the known interaction of RAD6/RNF20/RNF40 with the 
PAF elongation complex that is recruited by the elongation form of RNAPII (Laribee 





1.3.5 H2Bub1 and its regulation in human cancer 
The first evidence of an epigenetic link of monoubiquitinated H2B to cancer was 
shown by several reports that demonstrated the loss of H2Bub1 during 
carcinogenesis (Hahn et al., 2012; Prenzel et al., 2011; Shema et al., 2008; Urasaki 
et al., 2012). 
The first indication of a potential tumor suppressor role of RNF20 came from Shema 
et al. (2008) which demonstrated DNA hypermethylation of the RNF20 promoter in 
breast cancers. Further evidence was provided by the demonstration of oncogenic 
cell characteristics, like enhanced cell migration, growth in soft agar, and the ability of 
cells to form tumors in xenograft models. All these assays showed a higher 
oncogenic potential of RNF20-depleted cells. A strong decrease in expression of the 
tumor suppressor p53 upon RNF20-knockdown supports these results (Shema et al., 
2008). A previous study showed that RNF20 can stimulate p53-dependent 
transcription via its capability to bind p53 (Kim et al., 2005). Taken together, the 
results indicate that RNF20 has a tumor suppressor role but the role of RNF40 in 
tumor suppression remains largely unknown. Recently our group showed that siRNA-
mediated knockdown of the H2B ubiquitin ligase RNF40 decreases ER-induced 
gene transcription and supports estrogen-independent cell proliferation and activation 
of certain cell survival signaling pathways (Prenzel et al., 2011). Furthermore, a 
nearly complete absence of H2Bub1 was found in malignant and metastatic breast 
cancer tissues whereas strong signals for H2Bub1 expression was detected in 
adjacent non-transformed mammary epithelium, arguing for a decrease in H2Bub1 
expression concomitantly with tumor progression (Prenzel et al., 2011). Taken 
together these observations support a potential tumor suppressor role for H2B 
monoubiquitination and its ubiquitin ligases RNF20 and RNF40. 
 
1.4 Histone H2B deubiquitination 
H2B monoubiquitination is highly dynamic and its level is not only regulated by 
addition, but also by active removal of the ubiquitin residue from the chromatin. The 




deubiquitinases in different organisms. Ubp8, a subunit of the transcriptional co-
activator Spt-Ada-Gcn5-Acetylating complex (SAGA) which plays a role in regulating 
gene expression, was the first identified H2B deubiquitinase in S. cerevisiae (Daniel 
et al., 2004; Henry et al., 2003). Another ubiquitin protease, Ubp10 was shown to 
deubiquitinate H2B in S. cerevisiae independent of SAGA at distinct target loci. While 
Ubp8 functions at promoters of certain SAGA-dependent genes, Ubp10 is associated 
with non-transcribed regions and regulates silencing of telomeres, rDNA and other 
loci through histone H2B deubiquitination (Daniel et al., 2004; Emre et al., 2005; 
Gardner et al., 2005). The steady state levels of H2Bub1 were increased in ubp8 or 
in ubp10 cells but were further increased in a double ubp8 ubp10 mutant suggesting 
that these two deubiquitinases target different loci in the yeast genome (Emre et al., 
2005; Gardner et al., 2005). Buszczak et al. (2009) described the Drosophila gene 
scrawny, which regulates multiple types of stem cells. Scrawny is a USP family 
protein and deubiquitinates H2B. It shares homology with yeast Ubp10 within the 
core protease domain and closely matches human USP36 (Buszczak et al., 2009). In 
yeast the deubiquitinating enzyme Ubp8 is recruited to the gal1 promoter and the 
transcription of SAGA-responsive genes can be decreased upon its deletion (Kohler 
et al., 2006a). Furthermore, Ubp8 is known as part of the SLIK (SAGA-like) complex, 
where it catalyzes the differentially regulation of H3 methylation at some SAGA 
promoters (Lee et al., 2005). In isolation from other proteins Ubp8 is inactive (Lee et 
al., 2005) and is unable to bind to free ubiquitin (Ingvarsdottir et al., 2005). Thus, it 
was speculated that different binding partners induce conformational changes which 
regulate Ubp8 activity (Bonnet et al., 2008). 
1.4.1 The SAGA complex 
The yeast SAGA complex consists of 21 widely conserved proteins. The complex 
unites acetylating and deubiquitinating enzymatic activities. The main component of 
the acetylating complex is GCN5 – a bromodomain-containing protein that mediates 
acetylation of H3 (Grant et al., 1997). GCN5 was originally identified as a 
transcriptional co-activator in yeast and enhances transcription through its intrinsic 
acetyltransferase activity which facilitates acetylation of histones and non-histone 




The SAGA deubiquitination module (DUBm) is composed of Sgf11, Sus1 and Ubp8 
(Kohler et al., 2006b) with corresponding human orthologs ATXN7L3, ENY2 and 
USP22 (Fig. 4). The deubiquitination activity of the SAGA complex is highly 
conserved as revealed by the identification of Ubp8 orthologs in S. pombe (Ubp8), D. 
melanogaster (Nonstop) and human (USP22) (Helmlinger et al., 2008; Weake et al., 
2008; Zhang et al., 2008a; Zhao et al., 2008).  
1.4.1.1 USP22 as the main deubiquitinase for H2B 
Deubiquitination of H2B in humans is predominantly dependent on the SAGA 
complex and its disruption via ATXN7L3 knockdown leads to a great increase in the 
H2Bub1 level (Lang et al., 2011). However, the role of USP22 as the main DUB for 
H2B is not well established. Consistent with a potential tumor suppressor role of 
RNF20 and RNF40, oncogenic function is proposed for USP22 (ubiquitin-specific 
protease 22) that catalyzes deubiquitination, the opposite enzymatic reaction to 
RNF20 and RNF40. Transcriptional profiling of tumor cells generated an 11-gene 
signature associated with poor prognosis (Glinsky, 2005). USP22 was discovered as 
part of this group of genes. Two later reports described oncogenic effects of USP22 
in distinct transcriptional networks (Zhang et al., 2008a; Zhao et al., 2008). The first 
one identified USP22 as a positive regulator of MYC-dependent transcription 
potentially accounting for its oncogenic properties (Zhang et al., 2008a). USP22 was 
shown to be a positive regulator of p53-dependent transcription and RNF20 was 
described as a co-activator of p53-dependent activation of p21 and MDM2 (Kim et 
al., 2005). These findings hypothesize that only a correct balance between RNF20 
and USP22 activities may conduce to optimal p53-dependent transcriptional 
activation. Recently published data showed that USP22 is implied in the 
deubiquitination of H2B at the interferon-regulated gene IRF1 gene (Chipumuro and 
Henriksen, 2012) and is essential for androgen-dependent transcription (Zhao et al., 
2008). Thus, overexpression of USP22 may contribute to development of prostate 
cancer. An implication of USP22 in breast cancer was reported too, in part based on 
the finding that estrogen receptor (ER)-mediated transactivation requires USP22 
(Zhao et al., 2008). However, depletion of USP22 results in only a mild increase in 
the H2Bub1 level (Chipumuro and Henriksen, 2012; Zhang et al., 2008a; Zhao et al., 




proposed, where enzymatic activity of this enzyme depends on interactions with two 
other subunits of the deubiquitinating module (DUBm)  ATXN7 and ATXN7L3 
(Rodriguez et al., 2012). In addition it was reported that despite of USP22, ATXNL3 
and ENY2 are required for AR-mediated transactivation (Zhao et al., 2008).   
It is also possible that other ubiquitin hydrolases deubiquitinate H2Bub1 in addition to 
USP22. For example, the enzyme USP27X shares structural homology with USP22 
and is known to interact with it (Sowa et al., 2009) suggesting USP27X as another 
DUB for H2Bub1. Furthermore, a tblastn search revealed for both USP27X (31% 
over 478 amino acids) and USP51 (30% over 474 amino acids) a degree of 
homology to Ubp8 similar to that of USP22 (32% identity over 462 amino acids) 
(Johnsen, 2012a). To determine whether USP22, USP27X, USP51 and perhaps 
other DUBs contribute to deubiquitination of H2B and have overlapping functions in 
certain tissues, additional studies will be necessary. 
 
Fig. 4: The SAGA deubiquitination module is conserved from yeast to humans. (from Rodriguez-
Navarro, 2009) (A) The yeast DUB module is composed of Ubp8, Sgf11 and Sus1. The elimination of 
one of the subunits induces a loss of the other members and impairs SAGA association. (B) The 
human DUBm contains USP22, ATXN7L3 and ENY2. A direct interaction between ATXN7L3–USP22 
and ATXN7L3–ENY2 has been shown in human cells.  
 
1.4.1.2 The SAGA deubiquitination module  
The Sus1/ENY2 subunit of SAGA in yeast and humans is essential for transcription 






2009). ENY2 interacts with TREX-2 messenger ribonucleic acid (mRNA) export 
complex that acts at the interface between transcription and mRNP 
(ribonucleoprotein) export (Pascual-García and Rodríguez-Navarro, 2009). Thus, 
Sus1/ENY2 has many ‘satellite’ partners in interactions, and all of them together 
coordinate transcription, mRNP biogenesis and export (Kopytova et al., 2010a; 
Kurshakova et al., 2007). Some SAGA complexes that are present at the nuclear 
periphery also interact with the nuclear core complex (Kurshakova et al., 2007). 
Compared to Sus1/ENY2, much less is known about the function of the 
Sgf11/ATXN7L3 subunit of the DUB module (Gurskiy et al., 2012). Knockdown of the 
ATXN7L3 subunit of the SAGA complex leads to dissociation of USP22 from the 
SAGA complex whereas the other SAGA activities are preserved. In these cells, the 
H2Bub1 levels were strikingly increased (by 3-4 fold) demonstrating that the SAGA 
DUB activity is a major regulator of this modification and cannot be fully compensated 
by other deubiquitinases (Lang et al., 2011). Another SAGA subunit is ATXN7, a 
protein mutated in the inherited neurodegenerative disorder spinocerebellar ataxia 
type 7 (SCA7) (McCullough et al., 2012). 
1.4.1.3 Other H2Bub1 deubiquitinases 
In addition to USP22, several other DUBs have been identified as H2B DUBs in 
humans. Nicassio and colleagues reported that USP3 can remove ubiquitin from 
H2Bub1 in vivo and described USP3 as the closest human homolog of yeast Ubp8 
(Nicassio et al., 2007). Moreover, studies have described USP7 (also known as 
HAUSP) to be an H2B deubiquitinase in Drosophila and in human cells and functions 
as a major p53 regulator (van der Knaap et al., 2005, 2010). Analysis of mass 
spectrometry data identifies histones as interaction partners with the highest Z-scores 
for USP8 and USP44 (Sowa et al., 2009) and a recent report identified USP44 as an 
H2B deubiquitinase in ES cells (Fuchs et al., 2012). Single reports identified other 
H2B deubiquitinases in Drosophila or in A. thaliana but such activities were not 
reported for their human orthologs so far (Buszczak et al., 2009; Sridhar et al., 2007). 
Overall, it can be expected that in addition to SAGA, which appears as the major H2B 
deubiquitination complex in mammals, other DUBs will have specific effects in 




1.5 Nucleoli and stress conditions 
1.5.1 Nucleoli 
The nucleolus is one of the largest organelles in eukaryotic cells. The main function 
of the nucleolus is to carry out the initial steps of one of the most important cellular 
processes, ribosome biogenesis. This process must be tightly regulated to achieve 
proper cell growth and cellular proliferation (Lempiäinen and Shore, 2009). Beside 
the ribosome subunit biogenesis the nucleolus is involved in additional cellular 
functions (Pederson and Tsai, 2009), such as RNP biogenesis, cell-cycle control, 
apoptosis, DNA replication and DNA repair (Ahmad et al., 2009). 
With the help of electron microscopy three structural distinct subnucleolar 
compartments could be defined, the fibrillar centers where the transcription takes 
place, the dense fibrillar compartment here the rRNA processing happens and the 
granular component where the assembly of ribosomal subunits occurs (Boisvert et 
al., 2007). RNA polymerase I (RNAPI) transcribes rDNA genes, leading to the 
synthesis of a 47S precursor ribosomal rRNA transcript (pre-rRNA). The processing 
of pre-rRNA occurs either co- or posttranscriptionally and involves modifications like 
cleavage, methylation, and pseudouridylation of the primary rRNAs (Smith and Steitz, 
1997; Stoykova et al., 1985). Several ribonucleoprotein complexes control the 
cleavage and function to remove the external transcribed spacers (5′ETS and 3′ETS) 
and the internal transcribed spacers (ITS1 and ITS2). To form the small and large 
pre-ribosome subunits the 28S, 18S, and 5.8S rRNAs are assembled with ribosomal 
proteins. Final processing steps conduct the pre-ribosome subunits to become the 
mature 40S and 60S ribosome subunits (Boulon et al., 2010). 
1.5.2 Nucleolar reaction to stress 
All organisms need to react to conditions that influence their homeostatic balance. 
The cellular response to stress is an adjustment to environmental factors, such as 
nutrient supply, temperature or oxidative stress. Cellular stress can influence 
ribosome subunit production and cell growth (Mayer and Grummt, 2006). These 
stresses are often accompanied by drastic changes in the organization and structural 




inhibition causes nucleolar segregation, a well-described phenomenon (Al-Baker et 
al., 2004; Govoni et al., 1994). Segregation is marked by condensation followed by 
separation of the fibrillar centers and granular component, together with the formation 
of nucleolar caps from nucleolar and nuclear proteins around the nucleolar remnant 
(Shav-Tal et al., 2005). Stress conditions can alter the protein composition of the 
nucleolus very fast, indicating a complex reorganization during the stress response 
(Boisvert et al., 2010). Factors which are involved in nucleolar stress have been 
shown to translocate quite rapid so that some components change their localization 
already two minutes after adding the drug (Cohen et al., 2008). A typical mechanism 
of cell cycle regulation by nucleolar signaling involves the alteration of the p53 level. 
A previous report proposed a p53-dependent mechanism to redistribute ribosomal 
proteins from the nucleolus to the nucleoplasm (Boisvert and Lamond, 2010). In 
normally growing cells p53 protein levels are kept low due to its constant 
ubiquitination by the E3 ubiquitin ligase HDM2 which marks p53 for proteosomal 
degradation (Kruse and Gu, 2009). Different mechanisms which regulate the p53-
nucleolar signaling pathways therefore can induce increased cellular p53 levels (Lee 
and Gu, 2010). Furthermore, posttranslational modifications of nucleolar proteins 
may also be important for protein localization upon stress-induction (Boulon et al., 
2010). Importantly, a recent study described that a large variety of chemotherapeutic 
drugs activate ribosomal stress via inhibiting transcription and processing of 
ribosomal RNA (Burger et al., 2010). 
1.5.3 Nucleoli and JNK signaling 
Stress stimuli have been shown to activate c-Jun NH2-terminal protein kinase (JNK) 
family members. JNKs belong to the family of stress-activated protein kinases 
(SAPKs) and are implicated in cellular response to environmental stress and regulate 
the choice between survival and apoptosis (Chen et al., 1996). The activity of JNKs is 
induced by exposure to UV-B radiation, alkylating agents, hyperosmotic shock, 
proinflammatory cytokines and oxidative damage (Martindale and Holbrook, 2002; 
Song and Lee, 2007; Yoon and Kim, 2004). Activated JNKs phosphorylate several 
target proteins to change their activity and induce various biological effects. 
Phosphorylation of threonine and tyrosine residues in the T*PY* motif of JNK by 




TIF-1A, an essential transcription factor that modulates RNA polymerase I (RNAPI) 
activity (Mayer et al., 2005). Phosphorylated TIF-1A cannot interact with RNAPI and 
thus impairs the assembly of the transcription complex and rRNA synthesis. 
Furthermore, stress-induced inactivation of TIF-IA is associated with the translocation 
of TIF-IA from the nucleolus to the nucleoplasm. This shows the stress-induced 
release of nucleolar proteins to achieve different regulatory functions (Mayer and 
Grummt, 2005). 
1.5.4 AMPK signaling in tumorigenesis and tumor metabolism 
Metabolic reprogramming includes high rate of glycolysis followed by oxygen-
independent lactate fermentation. This observation is known as the Warburg effect 
and is a hallmark of cancer cells (Hanahan and Weinberg, 2011; Hsu and Sabatini, 
2008; Koppenol et al., 2011). Upon stress conditions tumor cells need this 
reprogramming to grow and survive (Christofk et al., 2008). AMP-activated protein 
kinase (AMPK) is a metabolic sensor that plays a central role in the regulation of 
cellular energy homeostasis. This highly conserved Ser/Thr protein kinase has been 
recently linked to stress resistance (Bungard et al., 2010; Jeon et al., 2012; Liu et al., 
2012). Due to its involvement in cellular stress resistance, AMPK has been linked to 
the regulation of tumorigenesis but the precise role remains unknown (Shackelford 





2.1 Technical equipment  
Agarose gel chamber     Harnischmacher Labortechnik, Kassel  
Balance       Sartorius AG, Göttingen  
Bandelin Sonoplus Sonicator   Bandelin electr. GmbH & Co. KG, Berlin  
Biological Safety Cabinet “Hera Safe”   Thermo Fisher Scientific, Waltham, USA  
Bioruptor       Thermo Fisher Scientific, Waltham, USA  
Centrifuge (Megafuge 1.OR)    Thermo Fisher Scientific, Waltham, USA 
Centrifuge 4°C (5417R)     Eppendorf AG, Hamburg  
C1000™ Thermal Cycler     Bio-Rad Laboratories GmbH, München  
CFX96™ Optical Reaction Module    Bio-Rad Laboratories GmbH, München  
Counting chamber (Neubauer)    Brand GmbH & Co. KG, Wertheim  
5100 Cryo 1°C Freezing Container    Thermo Fisher Scientific  
Electrophoresis & Electrotransfer Unit   GE Healthcare Europe GmbH, München  
Freezer -20°C      Liebherr GmbH, Biberach  
Freezer -80°C “Hera freeze”     Thermo Fisher Scientific, Waltham, USA  
Gel Imager “Gel iX imager”     Intas Science Imaging GmbH, Göttingen  
Incubator (bacteria)      Memmert GmbH & Co. KG, Schwabach  
Incubator (bacteria culture)    Infors AG, Bottmingen  
Incubator (cell culture) “Hera cell 150“   Thermo Fisher Scientific, Waltham, USA  
Inverse Microscope “Axiovert 40 CFL”   Carl Zeiss MicroImaging GmbH, 
Göttingen  
Luminometer 2030-100  Turner designs, Sunnyvale, CA, USA 
Magnet stirrer “MR3001”     Heidolph GmbH & Co. KG, Schwabach  
Microscope “Axiovert 40 C“   Carl Zeiss MicroImaging GmbH, 
Göttingen  
Microwave       Clatronic International GmbH, Kempen  




Pestle        Sartorius AG, Göttingen  
pH meter inoLab®      WTW GmbH, Weilheim  
Pipette Aid® portable XP     Drummond Scientific Co., Broomall, USA  
Pipettes “Research” Series     Eppendorf AG, Hamburg  
Power supply “Power Pack P25T”    Biometra GmbH, Göttingen Material 26  
Qubit® 2.0 Fluorometer.    Invitrogen GmbH, Karlsruhe  
Refrigerator       Liebherr GmbH, Biberach  
Repeat Pipette      Gilson Inc., Middleton, USA  
ScanScope XT      Aperio, Vista, CA, USA 
Scanner (CanoScan 8600F)     Canon GmbH, Krefeld  
Shaker “Rocky”      Schütt Labortechnik GmbH, Göttingen  
Table centrifuge (GMC-060)     LMS Co., Ltd., Tokyo, Japan  
Test tube rotator      Schütt Labortechnik GmbH, Göttingen  
Ultrapure Water System “Aquintus”    membraPure GmbH, Bodenheim  
Vacuum pump   Integra Bioscienc. AG, Zizers, Switzerland  
Vortex mixer       Scientific Industries, Inc., Bohemia, USA  
Water bath “TW 20”      JULABO Labortechnik GmbH, Seelbach  
X-Ray Cassettes     Rego X-ray GmbH. Augsburg 
 
2.2 Consumable materials  
Cellstar 6- and 12-well cell culture plate   Greiner Bio-One GmbH, Frickenhausen  
Cellstar PP-tube 15 and 50 ml    Greiner Bio-One GmbH, Frickenhausen 
Cellstar tissue culture dish 100×20 mm   Greiner Bio-One GmbH, Frickenhausen  
Cellstar tissue culture dish 145×20 mm   Greiner Bio-One GmbH, Frickenhausen  
Cell scraper (16 cm, 25 cm)     Sarstedt AG & Co., Nümbrecht  
Cryo Tube™ Vial (1.8 ml)     Thermo Fisher Scientific, Waltham, USA  




Gel blotting paper (Whatman paper)   Sartorius AG, Göttingen  
Glass coverslips (18 mm)     Gebr. Rettberg GmbH, Göttingen  
HybondTM-PVDF Transfer Membrane   GE Healthcare Europe GmbH, München  
Microtube 0,5 ml, 1.5 ml, 2 ml    Sarstedt AG & Co., Nümbrecht  
Microtube 1.5 ml, conical     VWR International GmbH, Darmstadt  
96 Multiply® PCR plate white    Sarstedt AG & Co., Nümbrecht  
96-well Multiplate® PCR plate white (low)   Bio-Rad Laboratories GmbH, München  
NORM-JECT Syringes of different volume  Henke Sass Wolf GmbH, Tuttlingen 
FrameStar® 96Skirted qRT-PCR plates  4titute Ltd., Wotton, UK 
Parafilm® “M”   Pechiney Plastic Packaging, Chicago, 
USA  
PET track-etched cell culture inserts   BD Bioscience, Franklin Lakes, NJ, USA  
Petri dish 92×16 mm      Sarstedt AG & Co., Nümbrecht  
Pipette tips       Greiner Bio-One GmbH, Frickenhausen  
Pipette filter tips      Sarstedt AG & Co., Nümbrecht  
Pippin Prep™ System  Invitrogen GmbH, Karlsruhe 
Protan® Nitrocellulose transfer membrane   Whatman GmbH, Dassel Material 27  
Shandon Coverplate      Thermo Fisher Scientific, Waltham, USA 
Syringe filter, Ca-membrane, 0,20 m  Sartorius AG, Göttingen 
Tissue microarrays     US Biomax,Inc., Rockville, MD, USA 
X-ray films “Super RX”    Fujifilm Corp., Tokyo, Japan  
 
2.3 Chemicals  
2.3.1 General chemicals 
Acetic acid       Carl Roth GmbH & Co. KG, Karlsruhe  
Adefodur WB developing concentrate   Adefo-Chemie GmbH, Dietzenbach  
Adefodur WB fixing concentrate    Adefo-Chemie GmbH, Dietzenbach  




Agarose       Carl Roth GmbH & Co. KG, Karlsruhe  
Albumin Fraction V (BSA)     Carl Roth GmbH & Co. KG, Karlsruhe  
Ammonium persulfate (APS)    Carl Roth GmbH & Co. KG, Karlsruhe  
Ammonium sulfate (NH4)2SO4   Carl Roth GmbH & Co. KG, Karlsruhe  
Aprotinin       Carl Roth GmbH & Co. KG, Karlsruhe  
Avidin-Peroxidase   ExtrAvidin®-Peroxidase, Sigma-Aldrich, 
St. Louis, USA 
Blasticidin   Invitrogen GmbH, Karlsruhe 
Bromophenol blue      Sigma-Aldrich Co., St. Louis, USA  
Calcium Chloride (CaCl2)    Carl Roth GmbH & Co. KG, Karlsruhe  
Chelex (Chelating Ion Exchange Resin)   Bio-Rad Laboratories GmbH, München  
 
Chloroform       Carl Roth GmbH & Co. KG, Karlsruhe 
Cholera Toxin       Sigma-Aldrich Co., St. Louis, USA 
Co-precipitant Pink     Bioline, Luckenwalde 
Colorless co-precipitant     Bioline, Luckenwalde 
Crystal violet       Sigma-Aldrich Co., St. Louis, USA  
Cytric acid       Carl Roth GmbH & Co. KG, Karlsruhe 
dATP        New England Biolabs, Frankfurt am Main 
DePeX mounting media     VWR International GmbH 
Diaminobenzidine substrate   ImmPACTTM DAB, SK-4105, Vector, 
Burlingame, USA 
Diethylpyrocarbonate (DEPC)    Carl Roth GmbH & Co. KG, Karlsruhe  
Dimethyl sulfoxide (DMSO)     AppliChem GmbH, Darmstadt  
Dithiothreitol (DTT)      Carl Roth GmbH & Co. KG, Karlsruhe  
DMEM       GIBCO®, Invitrogen GmbH, Darmstadt 
DMEM/F12       GIBCO®, Invitrogen GmbH, Darmstadt 
DMEM without Glucose    PAN Biotech GmbH, Aidenbach 
dNTPs       Promega GmbH, Mannheim 




Ethanol absolute      Th. Geyer GmbH & Co. KG, Renningen  
Ethidium bromide      Carl Roth GmbH & Co. KG, Karlsruhe  
Ethylenediaminetetraacetic acid (EDTA)   Carl Roth GmbH & Co. KG, Karlsruhe 
Epidermal Growth Factor (EGF)    Sigma-Aldrich Co., St. Louis, USA  
Fetal Bovine Serum (FBS)   Thermo Scientific HyClone, Logan, USA 
Material 28  
Formaldehyde      Sigma-Aldrich Co., St. Louis, USA  
Glycerol       Carl Roth GmbH & Co. KG, Karlsruhe  
ß-Glycerolphosphate (BGP)     Sigma-Aldrich Co., St. Louis, USA  
Glycine       Carl Roth GmbH & Co. KG, Karlsruhe  
GlycoBlue   Applied Biosystems/Ambion, Austin, USA  
Guava Nexin® reagent     Millipore GmbH, Schwalbach  
Hematoxyline (Mayer’s hemalaun solution)   Merck, Darmstadt 
Horse Serum       Sigma-Aldrich Co., St. Louis, USA  
Hydrochloric acid (HCl)     Carl Roth GmbH & Co. KG, Karlsruhe  
Hydrocortisone      Sigma-Aldrich Co., St. Louis, USA 
Insulin       Sigma-Aldrich Co., St. Louis, USA  
Isopropanol       Carl Roth GmbH & Co. KG, Karlsruhe  
Klenow fragment (3’ to 5’ exo-)    New England Biolabs, Frankfurt am Main 
Leupeptin       Carl Roth GmbH & Co. KG, Karlsruhe  
Magnesium chloride (MgCl2)    Carl Roth GmbH & Co. KG, Karlsruhe  
Methanol       M. Baker B.V., Deventer, Netherlands  
N-ethylmaleimide (NEM)     Sigma-Aldrich Co., St. Louis, USA  
NonidetTM P40 (NP-40)     Sigma-Aldrich Co., St. Louis, USA  
Opti-MEM       GIBCO®, Invitrogen GmbH, Darmstadt  
PBS tablets       GIBCO®, Invitrogen GmbH, Darmstadt  
Pefabloc SC Protease Inhibitor    Carl Roth GmbH & Co. KG, Karlsruhe  




Peptone       Carl Roth GmbH & Co. KG, Karlsruhe  
Potassium acetate (KOAc)     Carl Roth GmbH & Co. KG, Karlsruhe  
Potassium chloride (KCl)     AppliChem GmbH, Darmstadt  
Potassium dihydrogen phosphate (KH2PO4) Carl Roth GmbH & Co. KG, Karlsruhe  
Propidium iodide solution     Sigma-Aldrich Co., St. Louis, USA  
Protein A Sepharose CL-4B     GE Healthcare, Uppsala, Sweden  
RNase inhibitor      New England Biolabs, Frankfurt am Main  
RNAiMAX       Invitrogen GmbH, Karlsruhe  
Roti®-Phenol       Carl Roth GmbH & Co. KG, Karlsruhe  
Rotiphorese® Gel 30     Carl Roth GmbH & Co. KG, Karlsruhe  
Rotipuran® Chloroform     Carl Roth GmbH & Co. KG, Karlsruhe  
Rotipuran® Isoamylalcohol   Carl Roth GmbH & Co. KG, Karlsruhe 
Material 29  
Salmon sperm DNA      Stratagene, La Jolla, USA  
SepharoseTM CL-4B     GE Healthcare, Uppsala, Sweden  
Skim milk powder      Carl Roth GmbH & Co. KG, Karlsruhe  
Sodium acetate      Carl Roth GmbH & Co. KG, Karlsruhe  
Sodium chloride (NaCl)     Carl Roth GmbH & Co. KG, Karlsruhe  
Sodium deoxycholate     AppliChem GmbH, Darmstadt  
Sodium dodecylsulfate (SDS)    Carl Roth GmbH & Co. KG, Karlsruhe  
di-Sodium hydrogen phosphate dihydrate   Carl Roth GmbH & Co. KG, Karlsruhe  
Sodium hydroxide (NaOH)     Carl Roth GmbH & Co. KG, Karlsruhe  
Sodium pyruvate (Na-Pyr)     GIBCO®, Invitrogen GmbH, Darmstadt 
SureClean      Bioline GmbH, Luckenwalde 
SYBR Green       Roche Diagnostics GmbH, Mannheim  
TEMED       Carl Roth GmbH & Co. KG, Karlsruhe  
α,α-Trehalose Dihydrate     USB Corporation, Cleveland, USA  




Triton X-100       AppliChem GmbH, Darmstadt  
TRIzol® Reagent      Invitrogen GmbH, Karlsruhe  
Trypsin-EDTA (0.05%)     GIBCO®, Invitrogen GmbH, Darmstadt  
Tween-20       AppliChem GmbH, Darmstadt  
Xylene       Carl Roth GmbH & Co. KG, Karlsruhe 
Yeast Extract       USB Corporation, Cleveland, USA  
Zeocin       InvivoGen, San Diego, USA 
 
2.3.2. Inhibitors 
Acadesine (AICAR)     Biaffin GmbH & Co HG, Kassel 
Actinomycin D     Sigma-Aldrich Co., St. Louis, USA  
Cisplatin      Teva GmbH, Ulm 
CX-5461      Selleck, Houston, USA 
Doxorubicin      Enzo Life Sciences GmbH, Lörrach  
Iodacetamide      Sigma-Aldrich Co., St. Louis, USA  
Metformin      Sigma-Aldrich Co., St. Louis, USA  
NiCl2       Sigma-Aldrich Co., St. Louis, USA  
Sorbitol      USB Corporation, Cleveland, USA  
SP600125      Sigma-Aldrich Co., St. Louis, USA  
 
2.4 Kits and reagents  
ATP Determination Kit    Invitrogen GmbH, Karlsruhe  
Bioanalyzer DNA High Sensitivity Kit  Agilent, Santa Clara, USA 
Lipofectamine™ 2000     Invitrogen GmbH, Karlsruhe  
Lipofectamine™ RNAiMAX     Invitrogen GmbH, Karlsruhe  
PureYield™   Plasmid Midiprep Promega GmbH, 
Mannheim  




Qubit dsDNA HS Assay     Invitrogen GmbH, Karlsruhe 
SuperSignal® West Dura     Thermo Fisher Scientific, Waltham, USA  
SuperSignal® West Femto Maximum   Thermo Fisher Scientific, Waltham, USA  
 
2.5 Nucleic acids  
2.5.1 Vectors and expression constructs  
Name Reference 
pcDNA4/TO (Monroe et al., 2003) 
pcDNA4/TO-Flag-RNF40 (Kari et al., 2012) 
 
2.5.2 Oligonucleotides  
2.5.2.1 siRNA oligonucleotides  
Target Gene siRNA Target Sequence Source 
Target Gene  siRNA sequence 5‘-3‘ direction Source Cat.No. 
siGENOME 
Nontargeting 





Negative Control #1 
- Ambion 4390844 
AMPK1 
siGenome (#1) 
CAAAGUCGACCAAAUGAUA Dharmacon D-005027-01 
AMPK1 
siGenome (#2) 
GUAGAGCAAUCAAACAAUU Dharmacon D-005027-02 
AMPK1 
siGenome (#3) 
GACAAGCACUUACUCCAAA Dharmacon D-005027-03 
AMPK1 
siGenome (#5) 
ACAAUUGGAUUAUGAAUGG Dharmacon D-005027-05 
AMPK2  
siGenome (#2) 
GUACCUACGUUAUUUAAGA Dharmacon D-005361-02 
AMPK2  
siGenome (#3) 
GGAAGGUAGUGAAUGCAUA Dharmacon D-005361-03 
AMPK2  
siGenome (#4) 
GACAGAAGAUUCGCAGUUU Dharmacon D-005361-04 
AMPK2  
siGenome (#5) 
ACAGAAGAUUCGCAGUUUA Dharmacon D-005361-05 
ATXN7 
siGenome (#2) 
AAAGAAACCUGAAGACAAU Dharmacon D-011106-02 
ATXN7 
siGenome (#3) 






CAGGAAACCUCAGAAAUUG Dharmacon D-011106-04 
ATXN7 
siGenome (#17) 
CCAAAUAGCAAAUCGGUAC Dharmacon D-011106-17 
ATXN7L3 
siGENOME (# 1) 
GUCGAGAGCUCCCUGGAUA Dharmacon D-023237-01 
ATXN7L3 
siGENOME (# 2) 
GGUCGAGGAUUCUUGUUUG Dharmacon D-023237-02 
ATXN7L3 
siGENOME (# 3) 
UGAAUAAGUCUGAGAGUGA Dharmacon D-023237-03 
ATXN7L3 
siGENOME (# 4) 
GAGGCGAACCGUACGGAUU Dharmacon D-023237-04 
ENY2 
siGENOME (# 1) 
GAGAACGCCUCAAAGAGUU Dharmacon D-018808-01 
ENY2 
siGENOME (# 2) 
GAGCAGCGAUUAACCAAAA Dharmacon D-018808-02 
ENY2 
siGENOME (# 3) 
CCUGGUACCUGACAGUGUA Dharmacon D-018808-03 
ENY2 
siGENOME (# 4) 
GGCACACUGUAAAGAGGUA Dharmacon D-018808-04 
LKB1 
siGenome (#1) 
UGAAAGGGAUGCUUGAGUA Dharmacon D-005035-01 
LKB1 
siGenome (#3) 
GAGAAGCGUUUCCCAGUGU Dharmacon D-005035-03 
LKB1 
siGenome (#5) 
GCUCUUACGGCAAGGUGAA Dharmacon D-005035-05 
LKB1 
siGenome (#6) 
GCAUGACUGUGGUGCCGUA Dharmacon D-005035-06 
RNF20 AGCUCUUAUCCCGGAAGCUAA Ambion S32087 
RNF20 CAGGUCCGCAAGGAGUAUGAA Ambion S32088 
RNF40 AGAGAUGGAUGUGACAGGUCA Ambion S18960 
RNF40 AGGUACUACAGUUCAAGAACA Ambion S18962 
RNF40 










siGENOME (# 3) 
GAUCAAGGCCAACCAGAUUUU Dharmacon D-006913-03 
RNF40 




USP22 GGAGAGAAGUUUUCAACUU Ambion S23566 
USP22 
siGENOME (# 1) 
CCUUUAGUCUCAAGAGCGA Dharmacon D-006072-01 
USP22 
siGENOME (# 2) 
GGAAGAUCACCACGUAUGU Dharmacon D-006072-02 
USP22 
siGENOME (# 3) 





siGENOME (# 4) 
GGAGAAAGAUCACCUCGAA Dharmacon D-006072-04 
For transfections the Dharmacon siRNAs (#1 - #4) were pooled in a 1:1:1:1 ratio. 
2.5.2.2 RT-PCR primers  
Reverse transcription primers from Metabion AG, Martinsried. 
2.5.2.3 qPCR primers  
Primers utilized in qPCR in 5’ to 3’ orientation. Primers were obtained from previous studies 
or designed using a primer designing tool program (www.ncbi.nlm.nih.gov/tools/primer-
blast/).  
Name 5‘-3‘ sequence Reference 
28S rRNA GGGTAAGAAGCCATCAACCAAC (Prenzel et al., 2011) 
28S rRNA ATCAACCAACACCTTTTCTG (Prenzel et al., 2011) 
5.8S-ITS2 F CCGGGGCTACGCCTGTCTGA this study 
5.8S-ITS2 R TGCGCTTAGGGGGACGGAGG this study 
5’ETS-18S F GCTCGCCGCGCTCTACCTTAC this study 
5’ETS-18S R TTTCACTGTACCGGCCGTGCG this study 
ABCC2 F CACATGCTCCAGGCCAGTGTTTC this study 
ABCC2 F (hnRNA) CAGGGATTCCTGTGCATGGTGCTG this study 
ABCC2 F (hnRNA) CCGGCCTGTGGGTGTTGTGTC this study 
ABCC2 R TCCAGGTTCACATCTCGGACTGTGG this study 
ATXN7L3 F GTTGCCGCCCGCTGTGCTAT this study 
ATXN7L3 R AAGCCCGGCTGGTCCACGAT this study 
ENY2 F 1605 CCAACTGGTGCTCATGCTGCTGATT this study 
ENY2 R 1791 AGGCCACTTAGGCAACAGTGTGGA this study 
FST F ACCTACTCCAGTGCCTGCCACC this study 
FST F (hnRNA) CCCGAAGCCCTCCTGGCTGA this study 
FST R CACAGAGGGAACACCGGCCTCT this study 
FST R (hnRNA) AACAATCCGGGGCGCAGACG this study 
IL1B F CTGAACTGCACGCTCCGGGAC this study 
IL1B F (hnRNA) TGGGGTGACCCTGCACTGCT this study 
IL1B R CTTGAGGCCCAAGGCCACAGGT this study 
IL1B R (hnRNA) TGAGGCCCAAGGCCACAGGT this study 
ITS2-28S F GCGATTCCGTCCGTCCGTCC this study 
ITS2-28S R AGCGGGTCGCCACGTCTGAT this study 
RNF20 F TGGCCAAGCAGGAAGAAG (Karpiuk et al., 2012) 
RNF20 R ACGCTCTGACATGAGCTTGA (Karpiuk et al., 2012) 
RNF40 F AGTACAAGGCGCGGTTGA (Prenzel et al., 2011) 
RNF40 R GAAGCAGAAAACGTGGAAGC (Prenzel et al., 2011) 




RPLP0 F (hnRNA) AGATCAGGGACATGTTGCTGGCCA this study 
RPLP0 R CAGGGGCAGCAGCCACAAA (Fritah et al., 2005) 
RPLP0 R (hnRNA) AATGGCACCAGCACGGGCAG this study 
USP22 F AGCCAAGGGTGTTGGTCGCG this study 
USP22 R ACTGCCACCACGCCCGAAAG this study 
hnRNA = heterogeneous nuclear RNA 
 2.5.2.4 ChIP primers  
Primers utilized in ChIP in 5‟ to 3‟ orientation.  
Name 5‘-3‘ sequence Reference 
ABCC +192 3F TCCGGAGGCAGACCTGCCACT this study 
ABCC +2029 R ATTTATACACGTGGAGAAGCTGCCAGGG this study 
ABCC2 +138 R ATTCCTGGACTGCGTCTGGAACGA this study 
ABCC2 -5 F GGTTGGGATGAAAGGTCATCCTTTACGGA this study 
FST +116 R TTACCCTGGGCACTGCGGTCC this study 
FST +2018F CATCCCCGCCGGGTCTCCTT this study 
FST +2137R TGACGGAGCCAGCAGTTCCCA this study 
FST +67 F CTGCTGCTGCTGCTCTGCCAG this study 
GAPDH +1061F CCGGGAGAAGCTGAGTCATG (Shema et al., 2008) 
GAPDH +1111R TTTGCGGTGGAAATGTCCTT (Shema et al., 2008) 
GAPDH +67R AAGAAGATGCGGCTGACTGT this study 
GAPDH -122F CGGCTACTAGCGGTTTTACG this study 
IL1B +1137F TGGCAGTTCCTACAACGGGAGAACC this study 
IL1B +1234R AAAGCCCTGTCTGGGTGGCCTAG this study 
IL1B +3329F CTCCAGCTCTCCTAGCCAATACATTGCT this study 
IL1B +3473R TCAGCATCCAGTGCATGGCAGTCA this study 
IL1B +70R CGCTCAGGCCACAGCACTTCC this study 
IL1B -81F GCTCCCCATCTCTGCTTGTTCCACT this study 
RPLP0 +2439F CAGGTGTTTACTGCCCCACT this study 
RPLP0 +2609R AGCACAGCCTGGATAGCAAC this study 
RPLP0 +57 R CAATCAGAAACCGCGGATAG this study 
RPLP0 -85 F  CTTCGCGACCCTACTTAAAGG this study 
 
2.5.2.4 Primers for ChIP-seq library preparation  
Name 5‘-3‘ sequence Reference 





























































modified from Illumina 
 
2.6 Proteins  
2.6.1 Molecular weight standards  
Gene Ruler™ DNA-Ladder     Fermentas GmbH, St. Leon-Rot  
PageRuler™ Prestained Protein Ladder   Fermentas GmbH, St. Leon-Rot  
 
2.6.2 Enzymes  
Klenow DNA Polymerase     New England Biolabs, Frankfurt am Main 
Phusion Polymerase      New England Biolabs, Frankfurt am Main 
Proteinase K       Invitrogen GmbH, Karlsruhe  




Restriction enzymes      New England Biolabs, Frankfurt am Main  
Reverse Transcriptase (M-MuLV)    New England Biolabs, Frankfurt am Main  
RNase A       Qiagen GmbH, Hilden  
Streptavidin Peroxidase    Sigma-Aldrich Co., St. Louis, USA 
Taq DNA Polymerase     Prime Tech, Minsk, Belarus  
T4 Polynucleotide Kinase    New England Biolabs, Frankfurt am Main 
T4 DNA Ligase      New England Biolabs, Frankfurt am Main  
 
2.6.3 Antibodies  
2.6.3.1 Primary antibodies  
Antibodies used for ChIP and Western blot analyses and the respective dilutions. 
Name Clone Cat. Number WB ChIP Source 
ATXN7L3 - PA5-32017 1:1000 - Thermo Scientific 
H2Aub1 D27C4 8240 1:1000 - Cell Signaling 
H2B - 07-371 1:3000 - Millipore 
H2Bub1 56 05-1312 1:5000 2 µg Millipore (for IHC 
and WB) 
H2Bub1 7B4 - 1:100 - (Prenzel et al., 
2011) 
H2Bub1 D11 5546 - 2 µl Cell Signaling (for 
ChIP) 
H3K36me3 - ab9050-100 - 1 µg Abcam 
HSC70 B-6 sc-7298 1:25000 - Santa Cruz 
IgG (non-
specific) 
- ab46540 - 1 µg Abcam 
p-JNK - 46685 1:1000 - Cell Signaling 
RNAPII CTD4H8 MMS-128P - 1 µg Covance 
RNF40 KA7-27 R9029 1:1000 - Sigma 






1:1000 1 µg Sigma-Aldrich 
Prestige 
Actin - ab6276-100 1:10000 - Abcam 
 





2.7 Cells  
2.7.1 Bacteria cells  
Escherichia coli DH10BTM from Invitrogen GmbH, Karlsruhe. 





Donkey Anti-Mouse IgG-HRP 715-036-150 1:10000 
Jackson 
ImmunoResearch 







H1299 human lung carcinoma 
Prof. M. Dobbelstein, 
GZMB, Göttingen 
HCT116 wildtype human colon carcinoma 
Prof. M. Dobbelstein, 
GZMB, Göttingen 
MCF10A human breast 
nontumorigenic 
epithelial cell line 
Prof. M. Oren 
(Weizmann Institute of 
Science, Rehovot, Israel) 
U2OS human bone osteosaroma 
Prof. M. Dobbelstein, 
GZMB, Göttingen 
U2OS with stable Tet-R 
overexpression 
human bone osteosaroma 
Prof. T. Spelsberg, Mayo 
Clinic, USA 
U2OS with stable Tet-R-
RNF40 overexpression 
human bone osteosaroma 













Tris 0.1 M 
NaCl 1.5 M 
Tween-20 0.5% 
 
Western salts 10X 
Tris 0.25 M 
Glycin 0.86 M 
SDS 0.7 mM 
 
PBS-T 10X (pH 7,4) 
NaCl 0.73 M 
KCl 0.027 M 
NaH2PO4*7H2O 14.3 mM 
KH2PO4 14.7 mM 




CaCl2 0.9 mM 





PBS for cell culture 
1 PBS tablet per 500 ml ddH2O  
 
PBS-T  
PBS including 0.1% (w/v) Tween-20 
 
PCR-Mix 10X 
Tris-HCl (pH 8.8) 750 mM 
(NH4)2SO4  200 mM 
Tween-20 0.1% 
 
q-RT-PCR master mix 
PCR-Mix 1X 
MgCl2 3 mM 
SYBR Green 1:80000 
dNTPs 0.2 mM 
Taq-polymerase 20 U/ml 
Triton X-100 0.25% 
Trehalose 300 mM 
 
Pagano buffer 
Tris-HCl (pH 7.4) 20 mM 
DTT 2 mM 
EDTA 0.25 mM 
 
Deubiquitination buffer 
Tris-HCl (pH 7.4) 60 mM 
Glycerol 20%  















Chelex 10% (w/v) in H2O 
 
Nelson buffer (modified) 
NaCl 150 mM 
EDTA pH 8.0 20 mM 
Tris-HCl pH 7.5 50 mM 
NP-40 0.5% 
Triton X-100 1% 
NaF 20 mM 
 
Wienmann lysis buffer 
Tris-HCl pH 8.0 50 mM 
EDTA 10 mM 










ChIP dilution buffer (CDB)  
SDS 0.01% (wt/vol) 
Triton X-100 1.1% (vol/vol) 
EDTA 1.2 mM 
Tris-HCl pH 8.1 16.7 mM 
NaCl 167 mM 
 
Low-salt wash buffer 
SDS 0.1% (wt/vol) 
Triton X-100 1% (vol/vol) 
EDTA 2 mM 
Tris-HCl, pH 8.1 20 mM 
NaCl 150 mM 
 
Lithium chloride wash buffer  
LiCl 0.25M 
NP40 1% (vol/vol) 
Sodium deoxycholate 1% (wt/vol) 
EDTA 1 mM 
Tris-HCl, pH 8.1 10 mM 
 
TE buffer  
Tris-HCl pH 8.0 10 mM 
EDTA 1 mM 
 
2X Hybridization buffer 
Tris-HCl pH 7.5 20 mM 






Protease, phosphatase and deubiquitinase inhibitors 
Pefabloc 1 mM 
Aprotinin/Leupeptin 1 ng/μl  
BGP 10 mM  
NEM 1 mM 
IAA 10 μM 
NiCl2 1 mM 
 
DMEM cell culture “normal” medium 
Phenol red-free, high-glucose DMEM 
FBS 10% 
Penicillin 100 U/ml 
Streptomycin 100 μg/ml  
Sodium pyruvate 1 mM 
 
DMEM/F12 cell culture medium 
Phenol red-free, high-glucose DMEM/F12 
Horse serum 5% 
EGF 100 µg/ml 
Hydrocortisone 1 mg/ml 
Cholera toxin 1 mg/ml 
Insulin 10 mg/ml 
Penicillin 100 U/ml 










6X Laemmli buffer 




Bromphenol blue 0.02% 
 
LB Agar 





Yeast extract 0.5% 
NaCl 86 mM 
 
SDS separating gel (X%) 
Acrylamide X% 





SDS stacking gel (5%) 
Acrylamide 5% 








TAE buffer (50X) 
Tris 2 M 
Acetic acid 1 M 
EDTA 0.1 M 
 
Transfer buffer 
10× Western salts 10% 
Methanol 15% 
 
Citric acid buffer 
Citric acid (pH 6.0) 10 mM 
 
 
2.9 Software  
ModFit      Verity Software House, Topsham, USA 
Primer designing tool NCBI/Primer-BLAST 
(www.ncbi.nlm.nih.gov/tools/primer-blast/) 
ImageJ http://rsbweb.nih.gov/ij/ 
ChIP-seq analysis  European Nucleotide Archive 










3.1 Cell culture 
3.1.1 Culturing cells 
H1299 (human non-small cell lung carcinoma), HCT116 (human colon carcinoma) 
and U2OS (human osteosarcoma) cells were cultured in phenol red-free high-
glucose Dulbecco’s modified Eagles medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 100 units/ml penicillin, 100 µg/ml streptomycin and 1 mM 
sodium pyruvate at 37°C under 5% CO2 atmosphere. MCF10A (non-transformed 
epithelial cell line derived from human fibrocystic mammary tissue) cells were 
cultured in DMEM/F12 medium supplemented with 5% horse serum, 100 µg/ml EGF, 
1 mg/ml hydrocortisone, 1 mg/ml Cholera toxin,10 mg/ml Insulin, 100 units/ml 
penicillin and 100 µg/ml streptomycin under the same conditions. To culture U2OS 
TetR-RNF40 cells selective media containing Blasticidin (5 mg/ml) and Zeocin (500 
mg/l) was used. For the induction of the transgene cells were grown in the presence 
of 1 μg/ml doxycycline. 
3.1.2 Reverse-transfection with siRNA 
siRNA transfections were performed using Lipofectamine RNAiMAX according to the 
manufacturer’s instructions. For transfections in 6-well plate format for each well 30 
pmol of respective siRNAs were mixed with 500 μl of OptiMEM media. Then 5 μl 
Lipofectamine RNAiMAX were added and incubated for 10-20 min at RT. In the 
meantime H1299 or MCF10A cells were trypsinized and diluted in medium without 
antibiotics so that 2.5 ml contain 250,000 cells (MCF10A) or 150,000 cells (H1299). 
2.5 ml of the diluted cells were added to each well already containing the siRNA-
Lipofectamine RNAiMAX complexes. The medium was replaced with a fresh one 
after 24 h. Cells were harvested 48 h after transfection. For transfections in 10 cm 
format reagent amounts and cell number were scaled up four times. 
3.1.3 Colony formation assay 
Different number of cells depending on cell line and experiment were seeded in a 6-




proliferation of U2OS-Tet-R cells, cells were treated with doxycycline the following 
day. The medium was changed and doxycycline was added every second day. To 
analyze the proliferation of breast cancer and osteosarcoma cells upon siRNA-
mediated knockdown cells were transfected and after 24 h the respective number of 
cells were re-plated into a 6-well plate. After 8 days colonies were fixed with 70% 
methanol for 30 min on ice and then stained with 0.1% crystal violet solution (0.1% 
(w/v) crystal violet, 10% (v/v) formaldehyde) overnight. Stained colonies were rinsed 
thoroughly with water and then scanned with CanoScan 8600F.  
3.1.4 Migration assay 
Cell migration was assayed by seeding 100,000 MCF10A cells 48 hours after 
transfection with the respective siRNAs into 8.0 μm PET track-etched membrane cell 
culture inserts. The inserts were pre-equilibrate for at least 30 min with serum free 
medium. After pre-equilibration the medium was substituted by normal MCF10A cell 
culture medium either with or without 20 ng/ml EGF to induce cell migration. Cells 
were grown for another 48 h and were scraped gently from the upper layer of the 
inserts using a Q-Tip before fixation with 100% methanol for 10 min. Migrated cells 
were visualized by crystal violet staining for 10 min. Then, the inserts were rinsed 
twice in distilled water to remove excess staining. 
3.1.5 Measurement of DNA of single cells by flow cytometry 
In order to analyze the effects of RNF40 overexpression and siRNA-mediated 
knockdown of RNF20 and RNF40 on cell cycle progression, DNA content was 
measured via flow cytometry. MCF10A and U2OS cells were washed twice with PBS, 
harvested by trypsinization and pelleted by centrifugation. After resuspending the 
cells in 0.5 ml of PBS++, ice-cold ethanol was added dropwise to a final 
concentration of 75% ethanol. Cells were fixed overnight at 4°C. Before staining, the 
cells were centrifuged, rehydrated in PBS++ for 10 min, resuspended in PBS++ 
containing 0.5 mg/ml RNAse A and incubated at 37°C for 30 min. Cells were stained 
with 15 μl propidium iodide (1 mg/ml) and flow cytometry analysis was performed 
using the Guava EasyCyte plus FACScan. About 10,000 cells were analyzed for 
each sample. Distribution of cells in distinct cell cycle phases was determined and 




3.1.6 ATP determination assay 
MCF10A cells were cultured in a 6-well plate in normal or glucose free medium with 
and without 2-Deoxy-glucose. The medium was aspirated and the cells were washed 
twice with PBS with subsequent suspension in boiling water (1.0 ml/well) by repeated 
pipetting. The cell suspension was then transferred into a microcentrifuge tube for 
centrifugation (12,000g for 5 min at 4°C) and 20 l of the supernatant was used for 
bioluminescence measurement. The ATP assay was performed using an ATP 
determination kit according to the manufacturer’s instructions. The standard curve of 
ATP was obtained by serial dilutions of 10 M ATP solution. 
 
3.2. Molecular biology  
3.2.1 RNA isolation  
RNA isolation was performed with QIAzol® reagent according to manufacturer’s 
instructions. Cells were washed with PBS, lysed by addition of 1 ml of QIAzol® 
reagent to each well (6-well format) and collected into 1.5 ml tubes. After addition of 
200 μl of chloroform samples were vortexed and centrifuged at 10,000g for 20 min 
(4°C). After that the aqueous phase was collected and chloroform extraction was 
performed a second time followed by overnight isopropanol precipitation at -20°C. 
Then, samples were centrifuged at maximal speed of 12,000g for 20 min (4°C), 
pellets were washed twice with 70% ethanol, dried on vacuum concentrator and re-
dissolved in 50 μl of DEPC water. RNA concentration was measured using a 
NanoDrop.  
3.2.2 cDNA synthesis  
For DNA synthesis 1 μg of total RNA was mixed with 2 μl of 15 μM random primers 
and 4 μl of 2.5 mM dNTP mix and incubated 5 min at 70°C. After that 4 μl of reverse 
transcription master mix containing 2 μl 10x reaction buffer, 10 units of RNAse 
Inhibitor, 25 units of reverse transcriptase and 1.625 μl of DEPC water were added to 




inactivation for 5 min at 95°C. Finally, samples were brought to 50 μl volume by 
DEPC water. 
3.2.3 Quantitative real-time PCR  
One μl of each ChIP or cDNA sample was used for subsequent quantitative real-time 
PCR analysis with a final reaction volume of 25 μl. A PCR reaction was setup as 
follows: 75 mM Tris-HCl (pH 8.8), 20 mM (NH4)2SO4, 0.01% Tween-20, 3 mM MgCl2, 
200 μM dNTPs, 0.5 U/reaction Taq DNA Polymerase, 0.25% Triton X-100, 1:80,000 
SYBR Green I, 300 mM Trehalose and 30 nM primers. 
A two-step PCR protocol was used for each primer pair: 
  2 min – 95°C 
15 sec – 95°C 
  1 min – 60°C     x 40 
The PCR reaction was followed by a melting curve analysis from 60°C to 95°C with 
read every 0.5°C.  
ChIP and ChIP input samples were quantified using a standard curve made from 
ChIP input DNA. ChIP samples were normalized to their corresponding input 
samples and expressed as “percent input”.  
Also cDNA samples were quantified using a standard curve made from all cDNA 
samples. Prior to statistical analysis all qRT-PCR samples were normalized to 
RPLP0 or 28S ribosomal RNA as internal reference genes. The expression levels 
were determined relative to the control sample and expressed as “relative mRNA 
expression”. 
3.2.4 Microarray analyses  
Total RNA for microarray experiments was isolated as described in 3.2.1 and the 
Affymetrix DNA microarray analysis was performed at the Transcriptome Analysis 
Laboratory (TAL), University of Göttingen. The GeneChip® whole transcript labeling 
was carried out together with Susanne Luthin. Dr. Gabriela Salinas-Riester and 




The GeneChip® whole transcript sense targeting labeling assay (Affymetrix) 
generates amplified and biotinylated sense-strand DNA targets from the entire 
expressed genome. The GeneChIP® Whole Transcript Labeling Assay is based on 
the “GeneChIP® Whole Transcript (WT) Sense Target Labeling Assay Manual” 
(Affymetrix, Santa Clara, USA). This method is well established at the TAL and 
available as Standard Operating Procedure, SOP Nr. TAL027.1 “GeneChIP® Whole 
Transcript (WT) Labeling”. 
Target Preparation  
RNA for the Microarray analysis was isolated from cells as described above. First, 
RNA quality was checked using the Bioanalyzer 2100 (Agilent) to ensure GeneChip® 
whole transcript labeling of high-quality samples. This on-chip gel electrophoresis 
provides information about size, quantification and quality of RNA. Additionally, to 
estimate the integrity of RNA samples the RNA integrity number (RIN) is utilized.  
First of all, 300 ng of each total RNA sample were reverse transcribed into single-
stranded cDNA using T7-(N)6 primers. In order to generate double-stranded cDNA a 
second strand cDNA synthesis was generated, which in turn was used as a template 
for in vitro transcription (IVT). The IVT reaction was performed in the presence of T7 
RNA polymerase at 37°C for 16 h. In addition, the generated antisense cRNA 
samples were purified and then used for the second cycle of cDNA synthesis. In 
order to reproducibly fragment single-stranded DNA, dUTP was incorporated in the 
DNA during the first strand cDNA synthesis. After purifying the single-stranded cDNA 
samples, they were fragmented using a mix of uracil DNA glycosylase (UDG) and 
apurinic/apyrimidinic endonuclease 1 (APE 1). These enzymes specifically break the 
DNA at the dUTP residues not present in normal DNA. Afterwards, the single-
stranded DNA samples were labeled by using terminal deoxynucleotidyl transferase 
(TdT) and biotin-linked Affymetrix® DNA labeling reagent.  
Target Hybridization  
The target cocktail including fragmented and labeled target DNA as well as 
hybridization controls was prepared according to the manufacturer instructions for a 




was performed in the GeneChip® hybridization oven at 45°C with simultaneous 
centrifugation at 60 rpm for 17 h.  
Washing, staining and scanning of the array  
The GeneChIP® Fluidics Station 450 (Affymetrix, Santa Clara, USA) was used to 
wash and stain the probe arrays according to the manufacturer’s instructions. 
Subsequently, probe arrays were scanned with the GeneChIP® Scanner 3000 7G 
(Affymetrix, Santa Clara, USA). 
Data analysis 
The bioinformatics data analysis was performed by Frank Kramer in the Department 
of Medical Statistics, at the University of Göttingen, using log2 transformation and 
quantile normalization of expression levels (Bolstad et al., 2003). Background 
correction was applied according to the manufacturer’s advice. In order to determine 
significant differences of expression levels between the different groups a moderated 
Student’s t-test was computed on a gene-by-gene basis using the empirical Bayesian 
statistics in the ‘limma’ package (Smyth, 2004). P-values were adjusted for multiple 
testing using the Benjamini-Hochberg method (Benjamini and Hochberg, 1995) to 
avoid a high number of false positives and to stay below a false discovery rate of 5%.  
3.2.5 Chromatin immunoprecipitation (ChIP) 
Medium from growing cells was removed from plates and chromatin of the cells were 
crosslinked by adding 1% formaldehyde diluted in PBS to the cells. After 15 min of 
incubation at room temperature the crosslink was quenched by adding glycine to a 
final concentration of 125 mM. Cells were washed twice with PBS after 5 min and 
scraped in 1 ml of Nelson ChIP buffer. All further manipulations were performed on 
ice or at 4°C. Scraped cells were cleared from the buffer by centrifugation (12,000g x 
10 min) and washed again with 1 ml of Nelson ChIP buffer. After the second 
centrifugation the pellet was resuspended by softly pipetting up and down in 300 µl 
Weinmann lysis buffer containing protease, phosphatase and deubiquitinase 
inhibitors and incubated at 4°C on a wheel for 15 min. The sonication process was 
done in a Bioruptor (3 x 10 min) at “H” setting with 10 s breaks between 10 s pulses. 




min at 8°C) and pre-cleared with 100 µl of 50% slurry Sepharose beads for 1 h. After 
the pre-clearing the chromatin was centrifuged, aliquoted, frozen in liquid nitrogen 
and stored at -80°C. For the analysis 300 µl of chromatin were diluted up to 1 ml with 
ChIP dilution buffer and incubated overnight with the indicated amount of antibodies. 
Immunoglobulin bound complexes were precipitated by adding 30 µl of 50% slurry 
Protein-A or Protein-G Sepharose and incubation for another 2 h. After incubation the 
samples were centrifuged (2,000g x 2 min). The beads were washed with ice-cold 
low-salt wash buffer two times, LiCl wash buffer two times and TE buffer two times 
and the crosslink was reversed by adding 10% slurry Chelex with subsequent heating 
to 95°C for 10 min. The proteins in the sample were eliminated by adding 40 µg of 
Proteinase K and incubating for 30 min at 55° C. The samples were centrifuged 
(12,000g x 1 min) and the supernatant was analysed by quantitative real-time PCR. 
The background binding was determined by performing a ChIP with a non-specific 
IgG antibody. To prepare the ChIP inputs 10 μl (10% relative to ChIPs) of chromatin 
extracts were precipitated by adding 100% EtOH and 1 μl of Pink precipitant (5 
mg/ml) and incubating overnight at -20°C. The pellets were washed twice with 70% 
EtOH, dried and processed with Chelex addition as described above for ChIP 
samples. The ChIP samples were normalized to input DNA samples, and displayed 
as “% of input”.  
3.2.6 Chromatin immunoprecipitation-sequencing (ChIP-Seq) 
ChIP-seq combines chromatin immunoprecipitation with DNA sequencing to identify 
binding sites of DNA-associated proteins. The chromatin for the ChIP-seq was 
isolated and immunoprecipitated from cells as described above with the exception 
that after the last washing step of the beads, the DNA was isolated using phenol 
chloroform extraction.  
DNA isolation using phenol chloroform extraction 
For this purpose 50 μl of RNAse A (10 μg) diluted in 10 mM Tris, pH 8 was added to 
the washed chromatin-bound beads as well as the input samples and incubated 30 
min at 37°C. Afterwards 50 μl of Wienmann buffer and 20 µg of Proteinase K were 
added and the samples were incubated overnight at 65°C with a subsequent 




beads were rinsed again with 100 μl of Tris 10 mM pH 8. The samples were 
centrifuged and the supernatant was added to the first one. For extraction 10 μl of 8 
M LiCl, 4 μl co-precipitant and 200 μl phenol/chloroform/isoamyl alcohol (25:24:1) 
were added, samples were vortexed for 30 s and centrifuged for 2 min at full speed. 
The aqueous phase was collected and the phenol phase was back extracted with 
200 μl 10 mM Tris/HCl, pH 8 and 400 mM LiCl. After vortexing and centrifugation, the 
second aqueous phase was given to the first one and precipitation was performed by 
supplementation of 100 % EtOH and incubation for 2 h at -80°C. After that, samples 
were centrifuged at maximal speed for 30 min (4°C) pellets were washed with 70% 
ethanol, dried on vacuum concentrator and re-dissolved in 40 μl of water.  
5 μl of the DNA was used for qRT-PCR to confirm the efficient chromatin 
immunoprecipitation and 35 μl for ChIP-seq. DNA concentration was measured using 
a Qubit dsDNA HS assay on a Qubit® 2.0 Fluorometer. 
Shearing check 
In order to analyze the efficiency of the sonification a shearing check was performed. 
Therefore 10 μl of sheared chromatin were used for phenol chloroform extraction. 
After resuspension of the DNA in 15 μl Tris/HCl 10 mM, pH 8, 100 μg/ml RNAse A 
was added and the mixture was incubated 1 h at 37°C at 700rpm. The DNA was run 
on a 1.5 % agarose gel and when the shearing was sufficient a smear from about 
150 to 1 kb with a maximum around 300-400 bp was observed. 
Library preparation 
The cDNA library preparation was performed by Magali Hennion at the DZNE, the 
German Centre for Neurodegenerative Diseases within the Helmholtz Association. 
The ChIP-sequencing itself was carried out at the Transcriptome Analysis Laboratory 
(TAL), University of Göttingen. 
To start the library at least 10 ng of DNA is necessary. First, sonication process was 
perfomed on NGS Bioruptor by 10 cycles with 30 s on and 30 s off. Afterwards, DNA 
was checked for size, quantity and quality using Bioanalyzer DNA High sensitivity kit 
on a Bioanalyzer 2100 (Agilent). To perform end repair a reaction was setup as 




DNA polymerase (3 U), 1 µl Klenow DNA polymerase (1 U), 1 µl T4 PNK (10 U) and 
filled up with water to 50 µl total volume. After the incubation at 20°C for 30 min, 2 µl 
of colorless coprecipitant and 50 µL SureClean were added and the samples were 
vortexed and incubated for 10 min at RT. In addition, the samples were centrifuged 
(15,000g x 20 min) and the pellets were washed twice with 70% EtOH, dried and 
resuspended in 10 mM Tris/HCl, pH 8. Adding Adenosine nucleotides to the 3'-end of 
the DNA fragments occurs in a similar way described for end repair, except the 
composition of the master mix which contains: 5 µl 10X Klenow buffer, 10 µl 1 mM 
dATP, 1 µl Klenow fragment (3’ to 5’ exo-) (5 U) and the subsequent 30 min 
incubation was performed at 37°C. To ligate adapters to the DNA fragments 15 µl of 
2x T4 Quick ligase buffer, 16,7 nM Adapter oligo mix and 3 µl Quick ligase were 
directly added to the sample (final volume 30 μl) and incubated for 30 min at 25°C. 
Again precipitation and washing steps were carried out as described. In order to 
select and collect DNA with a well-suited size, Pippin Prep size (Sage Science) 
selection was performed. For this purpose samples were run on a 2% agarose 
cassette and selected from 200 bp to 300 bp. 
Five μl of DNA sample was used for subsequent quantitative real-time PCR analysis 
with a final reaction volume of 15 μl. A PCR reaction was setup as follows: 0.3 µl 
Primers PCR IndX + PCR 1.0 25 µM (500 nM final), 3 μl 5X HF buffer, 0,02 µl 
SybrGreen 1:100 and 0,15 µl Phusion polymerase (2 U/µl). 
The reaction was incubated under the following conditions: 
  1 min – 98°C 
10 sec – 98°C 
30 sec – 65°C 
30 sec – 72°C    x 30 
This quantitative PCR was used to determine the minimum number of PCR cycles 
needed to recover enough DNA for sequencing. A PCR to amplify 20 µl of DNA was 
carried out with 0.8 µl Primers PCR IndX + PCR 1.0 25 µM (500 nM final), 8 µl 5X HF 
buffer, 0.8 µl dNTP 10 mM and 0.4 µl Phusion polymerase (2 U/µl) and filled up with 




  1 min – 98°C 
10 sec – 98°C 
30 sec – 65°C 
30 sec – 72°C    x <18 (adjusted according to previous q-RT-PCR)  
Again precipitation and washing steps were carried out as described above and the 
amplified DNA concentration was measured by using the Qubit dsDNA HS assay and 
the size was checked using a Bioanalyzer. The enrichment of known positive sites 
was checked by qRT-PCR. 
The samples were pooled (4-6 samples/lane) and sequenced using Illumina HiSeq 
2000 following the manufacturer instructions. 
Data analysis 
The H2Bub1 ChIP libraries from two control and two ATXN7L3 KD samples were 
sequenced using Illumina HiSeq 2000. One input sample from each condition was 
also sequenced. Raw data were converted into fastq files. 30 to 39 million reads per 
sample were obtained. Data for H3K4me1, H3K4me3 and H3K9/14ac were obtained 
from the European Nucleotide Archive (http://www.ebi.ac.uk/ena/; study accession 
number SRP007976). The quality of the runs was checked with FastQC 
(www.bioinformatics.babraham.ac.uk/projects/fastqc/). The reads were mapped 
against the reference genome hg19 using Bowtie (http://bowtie-bio.sourceforge.net) 
with default parameters and wig files were generated with 10 bp windows using 
MACS (Zhang et al., 2008b). After combining the duplicates, metagene profiles for 
H2Bub1 were plotted using CEAS (Shin et al., 2009). The genes were sorted into 4 
quartiles according to gene expression level in control MCF10A cells (data obtained 
by our microarray). The same was done including input subtraction in the wig files 






3.3 Protein biochemistry  
3.3.1 SDS-PAGE 
Upon SDS-PAGE, the proteins were separated via sodium dodecylsulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970). Cells were lysed 
in RIPA buffer containing 1 mM Pefabloc, 1 ng/μl Aprotinin/Leupeptin, 10 mM BGP 
and 1 mM NEM. In order to shear genomic DNA, samples were sonicated for 10 s at 
10% power using a Bandelin Sonoplus sonicator. Protein samples were boiled in 
Laemmli buffer for 5 min and then subjected to SDS-PAGE. The composition of 
stacking and resolving gel are described in section 2.8. Polyacrylamide gels were run 
in SDS running buffer at 25 mA. 
3.3.2 Western blot analysis  
Subsequently, upon electrophoresis proteins were detected by Western blot analysis 
(Towbin et al., 1979) using target protein specific antibodies. Separated proteins 
were transferred at 25 V to PVDF membranes using transfer buffer for 1.5-2 h, 
depending on the size of the protein. The membranes were incubated for 30 min in 
PBS-T and 5% (w/v) dry milk to block non-specific antibody binding. Afterwards the 
membranes were incubated overnight at 4°C in the same blocking buffer containing 
the respective primary antibodies, diluted as described in the antibody table (2.6.3.1). 
After washing three times with PBS-T, the membranes were incubated for 1 h with 
the corresponding horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit 
IgG secondary antibodies at a dilution of 1:10,000. After washing three times with 
PBS-T, HRP signals were detected using enhanced chemoluminescence and 
exposed to X-ray films. 
3.3.3 In vitro deubiquitination assay 
Protein extracts from normal MCF10A cells (substrate) were mixed with extracts from 
cells where RNF20 and RNF40 were depleted with siRNA to minimize the level of 
H2Bub1 (effector). Cells were washed with PBS and scraped in Pagano buffer. After 
mixing cells were sonicated with tip sonicator for 15 s and centrifuged at full speed to 
remove the cell debris. One volume of target supernatant was mixed with one volume 




performed with shaking at 37°C for 15 min and stopped by adding Laemmli buffer 
and heating to 95°C for 5 min. The reaction products were analyzed by SDS-PAGE 
Western blot.  
3.3.4 Immunohistochemistry on paraffin sections 
Paraffin-embedded sections were de-paraffinized and rehydrated according to 
standard procedures. Briefly, after incubating in xylene for 20 min, the sections were 
rehydrated in a 100%, 90% and 70 % EtOH series before washing with PBS. 
Proteins were then unmasked by boiling slides in 10 mM citric acid/sodium-
phosphate. After washing with PBS, sections were quenched for endogenous 
peroxidase activity with 3% hydrogen peroxide in PBS for 45 min at RT and then 
blocked using 5% FCS diluted in PBS for 1 h at RT. The respective antibody was 
diluted 1:10 in PBS containing 5% FCS, applied and incubated overnight at 4°C in a 
humid chamber. Sections were washed using PBS before adding the biotinylated 
secondary antibody 1:200 diluted in PBS and incubated for 1 h at RT. PBS washings 
were followed by Avidin-Peroxidase incubation 1:1,000 diluted in PBS for 45 min. 
Staining signals were detected using diaminobenzidine substrate. Hematoxyline 
(Mayer’s hemalaun solution) was used for counterstaining. Histological slides were 
digitized with a ScanScope XT (Aperio) at 400x magnification. Color intensity 





H2B monoubiquitination (H2Bub1) is implicated in various cellular processes 
including gene expression, DNA damage repair and nucleosomal exchange. H2Bub1 
is associated with the transcribed region of active genes, and transcription is 
essential for maintaining global levels of H2Bub1. Misregulation of the H2Bub1-
modifying machinery is tightly linked with different types of cancer. The main focus of 
this study was to uncover mechanisms of H2Bub1 regulation upon stress-inducing 
factors.  
4.1 H2B ubiquitinating enzymes affect cellular responses 
To assess the function of H2B monoubiquitination the role of ubiquitin ligases 
involved was examined within a cellular context. Both RNF20 and RNF40 form an 
obligatory heterodimer in vivo. Consistent with its role within the major E3 ubiquitin 
ligase complex for histone H2B, RNF20 knockdown leads to a loss of global H2Bub1. 
Conflicting reports were published on the role of RNF40 in H2B monoubiquitination 
(Kim et al., 2005; Weake and Workman, 2008; Zhu et al., 2005). Our own working 
group could show that knockdown of either RNF20 or RNF40 using multiple siRNAs 
similarly decreased global levels of H2Bub1 (Pirngruber et al., 2009a). The main way 
to dissect H2Bub1 function experimentally is to deplete or overexpress one of its 
ubiquitinating enzymes and to analyze the resulting biological effects. Therefore, the 
siRNA-knockdown system was established for different cancer cell lines. The main 
focus was on MCF10A, a non-transformed breast epithelial cell line and U2OS, a 
human osteosarcoma cell line. 
4.1.1 Effects of RNF40 depletion on proliferation of breast cancer and 
osteosarcoma cells  
The colony formation assay is an in vitro cell survival assay which is based on the 
fact that a single cell can grow into a colony. The assay detects all cells which are 
able to produce progeny under specific experimental conditions. Therefore, it is the 
method of choice in this study to determine the effects of RNF40 depletion via siRNA-




Figure 5A shows the outcome of the clonogenic assay upon RNF40 knockdown. 
Different numbers of cells were seeded one day after transfection and analyzed 
seven days later. RNF40 depletion showed an anti-proliferative effect on both 
MCF10A and U2OS cells in this study, as depicted by a lower number of crystal 
violet-stained colonies compared to control cells. Western blot results in figure 5B 
showed that the RNF40 protein level is still reduced eight days after transfection. 
 
Fig. 5: siRNA-mediated knockdown of RNF40 increased colony formation in MCF10A cells and 
U2OS cells in vitro. (A) One day after reverse-transfection with 30 pmol control or RNF40 siRNA, 
transfected MCF10A cells were re-plated into 6-well plates with a density of 10,000 or 20,000 cells per 
well and U2OS cells with a density of 5,000 or 10,000 cells per well. Colonies were fixed with 70% 
methanol after eight days visualized by staining with 0.1% crystal violet. Representative images of the 
colonies formed in two independent experiments with both cell lines are shown. (B) In parallel, efficient 
knockdown of RNF40 eight days post transfection was confirmed by Western blot analysis a using 










































4.1.2 RNF20 and RNF40 depletion leads to a cell cycle arrest 
Next we analyzed whether or not the anti-proliferative effect of RNF20 and RNF40 
knockdown observed above may be due to the negative effects of these ligases for 
cell cycle progression. As shown in figure 6A, siRNA-mediated knockdown of RNF40 
in MCF10A cells increased the fraction of cells in G1 phase 72 h post transfection 
(56% in RNF40 vs. 43% in control-siRNA-transfected cells) while the percentage of 
cells in S phase (18% in RNF40 compared to 29% in control-siRNA-transfected cells) 
was decreased. RNF20 and RNF40 form a heterodimer complex and depletion of 
RNF20 effectively decreases amount of RNF40 but not vice versa which shows the 
requirement of RNF20 for RNF40 protein levels (Kim et al., 2009). Similarly to the cell 
cycle profile of RNF40 knockdown cells, RNF20 depletion showed a G1 cell cycle 
arrest with decreased cells in S phase. These observations suggest that siRNA-
mediated knockdown of RNF20 and RNF40 inhibits S phase entry and thus 
increases the G1 fraction of MCF10A cells. Decreased RNF20 and RNF40 levels 
seem to be sufficient to affect cellular metabolism and cause a G1 arrest or block S 
phase entry in MCF10A cells. Figure 6B shows that siRNAs targeting RNF20 and 






Fig. 6: Knockdown of RNF20 and RNF40 increases the percentage of MCF10A cells in G1 
phase.  (A) Cell cycle distribution of RNF20, RNF40 or control siRNA-transfected MCF10A cells was 
determined after 72h by staining with propidium iodide (PI) and analyzed by flow cytometry. 
Distribution of cells in distinct cell cycle phases was determined and graphically displayed using 
ModFIT cell cycle analysis software. The respective siRNAs are indicated above the ModFIT graphs. 
FACS profiles show G1 cell cycle arrest. In each case, 10,000 cells were analyzed. ± SD, n=4. The 
percentage of cells in distinct cell cycle phases is shown as a bar graph underneath. (B) Two different 
siRNA were used to deplete RNF20 and RNF40. The efficient knockdown was confirmed by Western 
blot analysis using a RNF40-specific antibody. - actin served as loading control. 
 
4.1.3 Effects of RNF40 overexpression on cell proliferation  
In order to determine the proliferation capacity in cells which overexpress RNF40 a 
stable cell line with inducible Flag-RNF40 expression was utilized. The benefit of 
using U2OS cells expressing Tet-R (Monroe et al., 2003) is the doxycycline-
inducibility of Flag-RNF40 overexpression which helps to avoid negative selection. 
An U2OS-Tet-R cell line was used as a control to exclude possible side effects of the 
doxycycline treatment. Both U2OS cell lines were treated with doxycycline and 







































DNA Content (PI) DNA Content (PI) DNA Content (PI)
G1:    51%  1.68
S: 24%  1.42
G2/M: 25%  0.30
G1:    43%  1.50
S: 29%  1.36
G2/M: 28%  1.89
G1:     56%  1.55
S: 18%  0.54























































to analyze RNF40 overexpression showed an increased level one and two days post 
doxycycline treatment compared to uninduced U2OS cells. However, the amount of 
H2Bub1 only showed also a slight increase compared to the increased expression 
level of RNF40. Since RNF20 and RNF40 act in a complex, RNF40 overexpression 
alone may not be sufficient to induce H2Bub1 levels to a greater degree. 
 
Fig. 7: Ectopic expression of RNF40 inhibits tumor cell growth. (A) Protein extracts were collected 
after 24 h and 48 h and were analyzed by Western blotting using antibodies to RNF40 and H2Bub1 to 
evaluate the induction of RNF40 and the concomitant increased H2Bub1 level. Analysis of H2B served 
as a loading control. (B) Effect of RNF40 overexpression on tumor cell growth in cultured human 
osteosarcoma cells, as determined by the colony formation assay. 2,000 and 5,000 U2OS cells 
expressing the RNF40-Tet-R were grown under Blasticidin (5 mg/ml) and Zeocin (500 mg/l) selection 
conditions and were seeded in a 6-well plate. The following day, cells were treated with doxycycline to 
induce RNF40 expression. The medium was changed every second day and after eight days colonies 
were fixed with 70% methanol and stained with 0.1% crystal violet. Representative samples from an 

































Analysis of the consequence of Flag-RNF40 overexpression eight days post 
doxycycline induction in U2OS cells by the colony formation assay (Fig. 7B) revealed 
a striking difference between RNF40 overexpressing and control U2OS cells. While 
control Tet-R cells showed a very similar proliferative capacity compared to 
doxycycline treated Tet-R cells, the Tet-R-RNF40 cells completely failed to form 
colonies upon doxycycline treatment to induce RNF40 expression (Fig. 7B). 
4.1.4 RNF40 overexpression induces a G2/M arrest in osteosarcoma cells 
In order to determine whether the anti-proliferative effect of doxycycline-induced 
RNF40 overexpression in U2OS-Tet-R-RNF40 cells involved alterations in cell cycle 
progression, flow cytometry analysis using propidium iodide (PI) was performed. 
Under normal conditions (control), 51% of the U2OS-Tet-R-RNF40 cells were in G1, 
40% in S and 9% in G2/M phase. RNF40 overexpression increases the fraction of 
Tet-R-RNF40 cells in G2/M phase (16% vs. 9% in control cells) (Fig. 8).  These data 
indicate that the negative effect of RNF40 overexpression on the colony formation 
capacity of Tet-R-RNF40 U2OS cells is due to an induced G2/M cell cycle arrest. 
All in all, these results showed anti-proliferative effects of siRNA-mediated 
knockdown of RNF20 or RNF40 on MCF10A and U2OS cell cycle progression as 





Fig. 8: RNF40 overexpression increases the percentage of U2OS-Tet-RNF40 cells in G2/M 
phase of the cell cycle.  Cell cycle distribution analyses of vector- and RNF40-transfected inducible 
U2OS-Tet-RNF40 cells. Cells were analyzed 48 h after doxycycline treatment to induce RNF40 
expression. For analysis of cell cycle distribution, U2OS-Tet-RNF40 cells were stained with propidium 
iodide (PI) and analyzed by flow cytometry using a FACScan. Distribution of cells in distinct cell cycle 
phases was determined and graphically displayed using ModFIT cell cycle analysis software. ± SD, 
n=3. The percentage of cells in distinct cell cycle phases is shown as a bar graph underneath.  
 
4.1.5 RNF20 and RNF40 similarly suppress migratory potential 
Based on results of the clonogenic assay, the flow cytometric analysis and the 
importance of cell migration for metastasis, we also investigated the effects of RNF20 
and RNF40 knockdown on the migratory potential of a normal mammary epithelial 
cell line. MCF10A cells are usually nonmigratory (Fig. 9 -EGF), but can be stimulated 
to migrate by addition of epidermal growth factor (EGF) (Fig. 9 +EGF). Consistent 
with a role for H2Bub1 in suppressing metastasis and with the previous study for 
G1:    51%  0.93
S: 40%  1.13












G1:     47%  0.29
S: 37%  0.71






























































RNF20 (Shema et al., 2008), siRNA-mediated knockdown of RNF20 or RNF40 
resulted in a strongly increased EGF-induced cell migration compared to control 
siRNA in MCF10A cells. Since enhanced cell migration is a distinctive feature of 
advanced tumors, this finding suggests that decreased RNF20/RNF40 expression 
may potentially facilitate cancer progression.  
 
Fig. 9: Cell migration assay after RNF20 or RNF40 knockdown. Control as well as RNF20 or 
RNF40 siRNA transfected MCF10A cells were seeded onto cell culture inserts and allowed to migrate 
for 48 h in either presence or absence of EGF. Representative images from an experiment with n = 2 
are shown, bar ¼ 500 mm. 
 
4.1.6 Messenger RNA expression profiling of RNF20 and RNF40-regulated 
genes 
As mentioned previously H2Bub1 was proposed to be required for transcriptional 
elongation and its depletion can result in altered gene expression. In order to address 
the possible involvement of the E3 ubiquitin ligases RNF20 and RNF40 in the 
regulation of mammalian gene expression, we performed expression microarray 
analysis on MCF10A cells after siRNA-mediated knockdown of endogenous RNF20 
and RNF40. In order to ensure that off-target effects do not create misleading results, 













Shema et al. (2008) generated microarray data from RNF20 depleted HeLa cells. 
Since no study so far investigated the role of RNF40 in the regulation of the 
mammalian gene expression (Fig. 10A), we performed expression microarray 
analysis for RNF40. In order to investigate whether the same set of genes were 
affected in MCF10A cells compared to the published results (Shema et al., 2008) and 
to check  the overlap of RNF20 and RNF40 regulated genes we used siRNA against 
both RNF20 and RNF40. Efficient knockdown of RNF20 and RNF40 and the 
subsequent near complete ablation of H2Bub1 was achieved as visualized by 
Western blotting with H2Bub1-specific monoclonal antibodies, whereas the HSC70 
protein level analyzed as a control was not significantly affected (Fig. 10B).  
The results of the expression microarray analysis are shown in figure 10A, which 
portrays the ratio between the expression level of each gene following RNF20 and 
RNF40 knockdown relative to their levels in cells transfected with control siRNAs. 
The mRNA expression profiling was accomplished by DNA microarray analysis for a 
total of 11,223 genes. The heatmap shows the fold-changes (FCs) in the expression 
of 525 genes which are significantly (q < 0.05) regulated by either RNF20 or RNF40 
depletion (FC < -log2 (1.5) or FC > log2 (1.5)).  
Previous genome-wide analysis revealed a general positive correlation between 
gene expression levels and steady-state H2Bub1 levels (Minsky et al., 2008). 
Nevertheless, the majority of transcribed genes in this microarray were not 
significantly affected by RNF20 and RNF40 knockdown and consequent reduction of 
H2Bub1. Yet, two subgroups of transcripts diverged significantly from the bulk 
transcriptome. One subgroup was down-regulated upon RNF20 and RNF40 
depletion (Fig. 10A, red), implying that H2Bub1 may be preferentially required for 
their efficient transcription. Interestingly, many transcripts were up-regulated in 
RNF20- and RNF40-depleted cells (Fig. 10A, blue), suggesting that their transcription 





Fig. 10: mRNA expression profiling of RNF20- and RNF40-regulated genes. (A) The heatmap 
shows fold-changes in experiments control siRNA vs. RNF20 siRNA, control siRNA vs. RNF40_1 
siRNA and control siRNA vs. RNF40_3 siRNA (columns) for genes which are significantly (q < 0.05; q 
= p-values adjusted to FDR) regulated by RNF20 oder RNF40 knockdown (FC < -log2 (1.5) or FC > 
log2 (1.5)) (rows). For siRNA-mediated knockdown, MCF10A cells were transfected with 30 pmol 
control, RNF20, RNF40_1 or RNF40_3 siRNA. Total mRNA was harvested 48 h after transfection and 
single-stranded cDNA fragments were generated, biotinylated and hybridized to Affymetrix DNA probe 
arrays. The arrays were scanned and analyzed as described. The color key is depicted on the top left 
side ranging from red marking down-regulated to blue marking up-regulated genes; mean values, n = 
3. FDR - false discovery rate, FC - fold-changes. (B) Efficient knockdown of RNF20, RNF40_1 and 
RNF40_3 and the resulting loss of H2Bub1 was confirmed by Western blot analysis using the 
indicated antibodies. HSC70 served as loading control. (C) Venn-Diagram showing the number of 
genes significantly regulated (q < 0.05, FC > log2 (1.5)) between pair-wise comparisons of RNF20, 




















The overlap in genes which were affected by transfection of the RNF20 siRNA or 
either of the individual RNF40 siRNAs is shown in the Venn-diagram in figure 6C. 
Only 29 genes were commonly regulated more than 50% (-1.5 fold) by all three 
siRNAs indicating that the maintenance of the MCF10A transcriptional profile occurs 
in an RNF20 and RNF40 independent manner. The correlation between the 
microarray data from RNF20 and RNF40 depleted cells and the control cells suggest 
that H2B monoubiquitination is not rate limiting for global transcription in MCF10A 
cells. These results rule out the hypothesis of general transcription failure upon 
RNF20 and RNF40 knockdown suggesting its influence in different mechanisms. 14 
of the commonly regulated genes were up-regulated while the expression of 15 
genes was decreased upon RNF20 and RNF40 depletion. 
Together, these results suggest that RNF20 and RNF40 siRNA-mediated reduction 
of H2B monoubiquitination correlates with strong up- or down-regulation of a specific 
subset of genes. 
4.1.6.1 RNF20 and RNF40 target gene expression  
The results of the microarray experiment on target gene expression were verified in 
quantitative RT-PCR (qRT–PCR) studies for three RNF20/RNF40-dependent genes 
(ABCC2, FST, IL1B) as well as for a gene whose expression was not affected by 
RNF20 and RNF40 depletion (gene RPLP0) and was therefore used as a control for 
normalization. The very efficient reduction of RNF20 and RNF40 transcripts as well 
as some strongly decreased transcripts of target genes in RNF20 and RNF40 siRNA-
transfected cells observed by microarray analysis could be confirmed in qRT-PCR 
experiments (Fig. 11A and B). 
ABCC2 is a member of the superfamily of ATP-binding cassette transporters and is 
involved in multi-drug resistance. Follistatin (FST) is an autocrine glycoprotein 
(Tortoriello et al., 2001).  Its primary function is the binding of members of the TGF-β 
superfamily, with a particular focus on activin, a paracrine hormone. Secreted TGF-
β1 induces epithelial-to-mesenchymal transition (EMT). The FST gene is a TGF-β 
antagonist found to be down-regulated in a EMT core signature (Taube et al., 2010). 
Furthermore, the activin A receptor ACVR1C for the TGFB family of signaling 




forms a cytokine protein that is an important mediator of the inflammatory response 
and is involved in a variety of cellular activities, including cell proliferation, 
differentiation, and apoptosis. IL-1β is forming a complex at the cell membrane with 
an interleukin 1 receptor and an Interleukin-1 receptor accessory protein (IL1RAP). 
Expression of the IL1RAP gene was also decreased in the microarray analysis and 
could be validated by qRT-PCR (data not shown). 
 
Fig. 11: qRT-PCR validation of selected genes from the microarray experiment. (A) MCF10A 
cells were transfected with siRNA to RNF20, RNF40 or control siRNA for 48 h. Total mRNA was 
harvested, reverse-transcribed with random primers and cDNA was subsequently analyzed via q-RT-
PCR. The expression levels of ABCC2, FST and IL1B genes were normalized to RPLP0 (control, 
shown in B) and graphed relative to control sample (set to one). The normalized expression levels 
were represented as “relative mRNA expression”; mean values ± SD, n=3. (B) Efficient knockdown of 
RNF20 and RNF40 was confirmed on mRNA level; mean values ± SD, n=3.   
 
4.1.7 H2Bub1 decreases during tumor progression 
Although a previous study indicated a potential tumor suppressor role for RNF20 
(Shema et al., 2008), at the time this project began no study had investigated the 
presence of H2Bub1 in normal and cancerous tissues. In order to examine the 
validity of H2Bub1 and its ubiquitin ligase RNF40 as potential tumor suppressors, it 
was necessary to investigate their expression levels in primary tumor samples. 
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published branched-peptide antigen strategy (Minsky et al., 2008) and a commercial 
available antibody for RNF40 and carried out immunohistochemical analysis of tissue 
microarrays containing normal tissue as well as malignant cancer samples. As a 
representative example normal colon tissue versus colon cancer tissue is shown (Fig. 
12). Compared to normal colon tissue, nuclear staining of H2Bub1 is decreased in 
colon cancer tissue (Fig. 12, top panels). Stromal cells are connective tissue cells of 
any organ and cancer cells often require nearby stromal cells for their own 
proliferation. As expected, stromal cells visible in this tissue microarray are H2Bub1 
positive confirming that the decreased H2Bub1 staining during colon cancer 
progression is due to decreased monoubiquitination of H2B and not due to a lack of 
sample antigenicity.  
 
Fig. 12: H2Bub1 and RNF40 expression in human normal colon tissue and tumors.  
Representative immunohistochemical image displaying H2Bub1 and RNF40 protein expression. 
















In addition, the same tissue microarray samples were used for immunohistochemical 
staining for RNF40. No significant changes in RNF40 levels could be observed 
between normal and cancer colon tissue (Fig. 12, bottom panels). Since down-
regulation of RNF20 leads to decreased RNF40 levels we emanate that H2Bub1 
regulation in the tissue microarray samples is independent of both RNF20 and 
RNF40 expression. Thus, it seems that different regulator mechanisms exist since we 
observed a strong decrease in H2Bub1 nuclear staining in tumor compared to normal 
tissue. A possible explanation could be the involvement of upstream mechanisms 
such as the regulation of Cyclin-dependent kinase 9 (CDK9) or WAC which both 
interact with the RNF20/RNF40 complex and participates in the regulation of H2Bub1 
levels (Pirngruber et al., 2009a; Zhang and Yu, 2011). An active suppression of 
H2Bub1 accumulation is also possible, since in several tumors ubiquitin specific 
protein 22 (USP22) is overexpressed (Liu et al., 2010, 2011; Zhang et al., 2011) or 
the RNF20 promoter is hypermethylated down-regulating RNF20 gene expression in 
breast cancer (Shema et al., 2008). USP22 is a deubiquitinating enzyme and was 
identified as one of the ‘stem cell signature’ genes whose overexpression correlates 
with poor cancer prognosis (Glinsky, 2005). Further analyses of USP22 and the 
interacting subunit ATXN7L3 which are components of the human SAGA 
deubiquitinating module complex (Kohler et al., 2010) were done in subsequent 
experiments. 
These preliminary results were further investigated by a colleague and the results 
were recently published in Prenzel et al., (2011). 
Taken together, all these data show a potential tumor-suppressor role for H2Bub1. 
4.1.8 Genomic regulation of ATXN7L3 and USP22 in breast cancer 
ONCOMINE, a cancer microarray database and web-based data-mining platform 
aimed at facilitating discovery from genome-wide expression analyses. Differential 
expression analyses comparing most major types of cancer with respective normal 
tissues as well as a variety of cancer subtypes and clinical-based and pathology-
based analyses are available for exploration (Rhodes et al., 2004). ONCOMINE data 
for USP22 and ATXN7L3 expression in normal breast tissue compared to breast 




ATXN7L3 in the carcinoma tissue (Fig.13). These results strengthen the hypothesis 
that efficient deubiquitinases constantly work to remove H2Bub1. The described 
results are an important basis for further studies on the regulatory mechanism of H2B 
monoubiquitination. 
 
Fig. 13: Genomic regulation of ATXN7L3 and USP22 in breast cancer. Examination of the 
Oncomine database reveals a significant increase in ATXN7L3 and USP22 levels in different types of 
breast carcinoma. (Individual P-values and N indicated for each data set.) 
 
 
4.2 H2Bub1 levels decrease following various stress conditions 
H2B monoubiquitination is highly dynamic and its level is regulated by addition and 
removal of the ubiquitin residue from the chromatin.  
4.2.1 Different stress factors rapidly reduce H2B monoubiquitination 
In the course of this study immortalized MCF10A cells, a non-transformed epithelial 
cell line derived from human fibrocystic mammary tissue and H1299, a human non-
small cell lung carcinoma cell line were treated with a variety of agents to test their 
effects on H2Bub1 levels. Earlier reports showed a severe reduction of histone 
H2Bub1 by a number of different factors. Actinomycin D inhibits transcription via 
binding DNA at the transcription initiation complex and prevents the elongation of 
RNA (Sobell, 1985). Several studies demonstrate that Actinomycin D is able to 
reduce H2Bub1 levels already at low concentrations rapidly confirming the 





Murphy, 1990; Minsky et al., 2008; Pirngruber et al., 2009a). The study from Davie 
and Murphy (1990) showed a loss of monoubiquitinated H2B upon heat-shock 
treatment as well. Further, DNA damage was also suggested to reduce H2Bub1 
levels (Lis and Romesberg, 2006) and Minsky et al. (2008) showed a significant 
decrease in H2Bub1 upon Doxorubicin treatment. In agreement with these reports we 
observed a drop in this histone mark by Actinomycin D, Doxorubicin and heat-shock 
treatment as well (Fig. 14). Consistent with these studies, we could show that the 
important anticancer drug Cisplatin (Fig. 14A), which is able to form adducts with 
DNA (Kartalou and Essigmann, 2001) reduces global H2Bub1 levels as well. In 
addition, the present study demonstrated that osmotic stress in terms of Sorbitol 
treatment nearly abolish H2Bub1 levels dose dependently as shown in figure 14A. To 
establish which dose is necessary to reduce the level of H2Bub1 in MCF10A cells, 
concentration courses were performed. Based on these data, all the following stress-
inducing experiments were performed using 20 nM Actinomycin D and 50 M 
Cisplatin.  
 
Fig. 14: Various factors down-regulate H2B ubiquitination.  (A) MCF10A cells were treated for 12 
h with increasing concentrations of Actinomycin D, Cisplatin and Sorbitol. Whole protein extract were 
harvested and analyzed via Western blot using specific H2Bub1 antibody. H2B is shown as a loading 
control. (B) HCT116 cells were treated with the indicated concentrations of Doxorubicin for 6 h. Protein 
extracts were subjected to Western blot analysis. (C) MCF10A cells were heat shocked (HS) by 



















4.2.2 Treatment with stress-inducing factors alters RNF20- and RNF40- 
regulated gene transcription 
In order to test whether the expression of RNF20- and RNF40- regulated genes are 
also influenced by cellular stress which decrease H2Bub1 levels, MCF10A cells were 
treated with Actinomycin D and Cisplatin. To verify the efficient loss of H2Bub1 upon 
treatment protein extracts were analyzed via Western blot using a specific antibody 
against H2Bub1 (Fig. 15A). Examination of the mRNA levels of the ABCC2, FST and 
IL1B genes by qRT-PCR showed a strong decrease in gene transcripts upon 
treatment, while RPLP0 as a control remained largely unaffected or slightly increased 
(Fig. 15B).  
 
Fig. 15: Different stress factors decrease RNF20 and RNF40 target gene expression. (A) 
MCF10A cells were treated with 20 nM Actinomycin D for 3 h or 50 mM Cisplatin for 12 h. mRNA 
samples were analyzed via qRT-PCR and expression levels were represented as described in figure 
11; mean values ± SD, n=3. (B) Whole protein extracts were analyzed via Western blot using 
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4.2.2.1 Actinomycin D affects rRNA transcription 
Most drugs require specific transport mechanisms and other stress inducing factors 
need subsequent steps to get inside the cell and cause transcriptional changes. In 
order to analyze the dynamics on global H2Bub1 level upon ribosomal stress we 
treated cells with Actinomycin D. From the results of a time course treatment it is 
clear that a significant loss of H2Bub1 already happens within 30 min after treatment 
(Fig. 16B) indicating that H2B ubiquitination and deubiquitination are very fast and 
highly dynamic processes. 
At low concentrations Actinomycin D is a potent RNAPI inhibitor and leads to 
ribosomal stress via rapidly disrupting the function of nucleoli by blocking ribosomal 
RNA transcription (Perry & Kelley, 1968). Concentration course studies showed that 
the decrease of H2Bub1 and activation of the stress-responsive kinase JNK happen 
in the same range of concentrations (Fig. 16C). The JNK pathway is introduced in the 
subsequent chapter 4.3.1. Since H1299 cells used in the experiment were p53-
negative the observed effects are independent of the p53 pathway. 
To determine if loss of global levels of H2Bub1 correlates with the inhibition of RNAPI 
we checked for transcribed rRNA genes. 18S, 5.8S, and 28S rRNAs are transcribed 
as a single large precursor molecule (Fig. 16A). Processing steps of this pre-rRNA 
are investigated to check how fast Actinomycin D influences the rRNA transcription 
rate. During the processing transcribed spacer RNA gets removed and is rapidly 
degraded. Evaluation of the internal transcribed spacer (ITS) ITS 2 to 28S, the 5’ETS 
(external transcribed spacer) to 18S and 5.8S to ITS2 RNA expression level using 
qRT-PCR revealed, that Actinomycin D treatment resulted in a decreased rRNA 
transcription even after 30 min (Fig. 16D). To normalize the data primers for total 28S 
rRNA were used. Thus, inhibition of RNAPI activity coincides with decreased H2Bub1 





Fig. 16: H2Bub1 reduction happens very rapidly and affects rRNA transcription. (A) Scheme of 
the assembly of rRNA into the ribosomal subunits. In eukaryotes, each cytoplasmic ribosome 
comprises four different molecules of RNA: two large rRNAs designated 18S and 28S and two small 
rRNAs termed 5S and 5.8S. While all four rRNAs of cytoplasmic ribosomes are encoded in nuclear 
genes, the 18S, 5.8S, and 28S rRNAs are transcribed as a single large precursor molecule. Post-
transcriptional processing of this pre-rRNA in the nucleolus subsequently yields separate mature 
rRNAs that assemble with numerous ribosomal proteins to form the ribosomal subunits (modified from 
Gillespie et al. (2006)). (B) MCF10A cells were treated with 20 nM Actinomycin D and harvested for 
Western blot after indicated times. (C) MCF10A cells were treated with indicated concentrations of 
Actinomycin D for 12 h. Proteins were analyzed by Western blot using the indicated antibodies. (D) 
MCF10A cells were treated with 20 nM Actinomycin D for the indicated times. Total mRNA was 
harvested, reverse-transcribed with random primers and analyzed with qRT-PCR. The expression 
levels were normalized to 28S ribosomal RNA as an internal reference gene. The normalized 
expression levels are graphed relative to control sample which is set to one. The expression levels are 
represented as “relative mRNA expression”. ETS - external transcribed spacer; ITS - internal 
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4.2.2.2 Actinomycin D concentration specifically affects RNF20 and RNF40 
target gene transcription 
Actinomycin D is an antibiotic known to inhibit RNAPI at low doses and RNAPII at 
high doses. In order to check whether the utilized level of Actinomycin D already 
inhibits the general RNAPII transcription we evaluated heterogeneous nuclear RNA 
(hnRNA) using primers which span exon-intron boundaries by qRT-PCR. Eukaryotic 
pre-mRNA includes two different types of segments, exons and introns and it exist 
only briefly before it is fully processed into mRNA. Thus hnRNA levels closely reflect 
the transcriptional activity of the investigated gene. Consistent with the observed 
decrease in H2Bub1 a highly significant reduction in mRNA expression of the RNF20 
and RNF40 target genes ABCC2, FST and IL1B upon treatment of Actinomycin D for 
either 3 h or 6 h was detected. The expression of RPLP0 was used as a negative 
control and remained largely unchanged (Fig. 17). 
 
Fig. 17: RNF20 and RNF40 target gene expression but not general RNAPII transcription is 
affected upon Actinomycin D treatment.  MCF10A cells were treated with 20 nM Actinomycin D for 
3 h and 6 h. RNA was isolated and cDNA was analysed by qRT-PCR using hn primers. Gene 
expression was normalized to hnRPLP0 expression (indicated as “relative mRNA expression“). hn – 
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4.2.2.3 Cisplatin affects H2Bub1 occupancy 
The medical relevance of Cisplatin in anticancer treatment disposes us to investigate 
the effect of Cisplatin treatment on H2Bub1 occupancy in MCF10A cells by 
performing chromatin-immunoprecipitation (ChIP) experiments. Two highly 
expressed genes, RPLP0 and GAPDH demonstrated decreased H2Bub1 occupancy 
on their transcriptional start sites (TSS) and their transcribed regions (TR) (Fig. 18). 
In general, H2Bub1 is higher at the TR compared to the TSS consistent with previous 
reports which showed that H2Bub1 in humans is preferentially found in the 
transcribed regions of highly expressed genes and is therefore suggested to be 
linked to transcriptional elongation (Fleming et al., 2008; Minsky et al., 2008). After 
verifying the efficient H2Bub1 reduction the level of trimethylated lysine 36 in histone 
H3 (H3K36me3), which was used as a control, was examined. No difference in 
H3K36me3 occupancy in the presence or absence of Cisplatin could be observed. 
Trimethylation of H3K36 is associated with the coding region of genes and correlates 
with active transcription (Krogan et al., 2003). The connection to transcriptional 
elongation and the independence on the H2Bub1 driven transhistone pathway 
(Briggs et al., 2002) makes H3K36me3 to a useful control to show that global histone 





Fig. 18: Chromatin immunoprecipitation (ChIP) analysis revealed a decrease in H2Bub1 
occupancy upon Cisplatin treatment.  Chromatin extracts were analyzed by ChIP for H2Bub1 and 
H3K36me3 using a specific antibody. Non-specific IgG was used to distinguish between specific and 
background binding (depicted as dotted line). ChIP samples were normalized to input samples and 
expressed as “percent input”. Mean values   SD, n=3.  
 
In summary, RNF20 and RNF40 dependent genes and the H2Bub1 level is reduced 
upon Cisplatin treatment, but global histone modifications like H3K36me3 seems to 
be unaffected. 
4.2.2.4 RNAPI inhibitor decreases H2Bub1 level similar to Actinomycin D 
To verify if the loss of H2Bub1 upon Actinomycin D treatment is because of RNAPI 
inhibition and not due to possible side effects, a specific RNAPI inhibitor which 
selectively inhibits rRNA synthesis in the nucleolus, but does not inhibit mRNA 
synthesis was used. Thus, selective inhibition of RNAPI by CX-5461 may offer a 
general therapeutic strategy to block cancer cell proliferation, as potent anti-
proliferative activity in cancer cells and xenografts is described (Drygin et al., 2011). 
We found that already 15 min after nucleolar stress induction via the RNAPI inhibitor 






































































min compared to the non-treated control cells (Fig. 19). Taken together, these results 
demonstrate that nucleolar stress-inducing factors inhibiting RNAPI decreases the 
H2Bub1 level globally, while the general RNAPII transcription remains unaffected. 
 
Fig. 19: The specific RNAPI inhibitor CX-5461 decreases H2Bub1 level.  MCF10A cells were 
treated with 20 mM CX-5461. H2Bub1 protein levels were analyzed by Western blotting using specific 
antibody against H2Bub1. H2B served as loading control.  
 
 
4.3 Cellular stress activates several signaling pathways 
Chromatin modifications alter in response to different stresses. Since the 
concentration of stress inducing factors where cells develop a strong DNA-damage 
response is much lower than the concentration where H2Bub1 levels were affected, 
we analyzed several signaling pathways which are known to be activated by cell 
stress and potentially lie downstream of the DNA-damage response to determine if 
they are involved in the stress-induced loss of H2Bub1. 
4.3.1 JNK activity regulates the level of H2B ubiquitination 
Activation of c-Jun N-terminal kinases (JNKs) is a hallmark of various stress 
inducers. Inflammatory signals, for example exposure to UV-B radiation, protein 
synthesis inhibitors, and a variety of stress stimuli can activate JNK (Song and Lee, 
2007; Yoon and Kim, 2004). To determine whether increased JNK activation might 
be essential for the stress-induced loss of H2Bub1 we used a specific JNK inhibitor 
SP600125. Indeed, pretreatment with the JNK inhibitor partially blocked the ability of 
Actinomycin D to decrease global H2Bub1 levels (Fig. 20). Decreased protein levels 
of phosphorylated JNK upon JNK inhibitor treatment compared to the untreated 
control MCF10A cells confirmed the efficiency of the JNK inhibitor. 
H2Bub1
H2B





Fig. 20: JNK inhibition interferes with Actinomycin D-inducible H2Bub1 deubiquitination.  
MCF10A cells were pretreated with 20 μM of JNK inhibitor SP600125 for 1 h and then treated with 256 
nM of Actinomycin D for 3 h. Protein extracts were harvested and analyzed by Western blotting. 
Phospho-JNK shows two bands since the antibody detects endogenous levels of JNK dually 
phosphorylated at threonine 183 and tyrosine 185.  
 
4.3.2 Regulation of H2B ubiquitination upon AMP signaling 
Metabolic reprogramming is associated with tumorigenesis and tumor metabolism 
(Shackelford and Shaw, 2009). The AMP-activated protein kinase (AMPK) is a 
metabolic sensor that helps maintain cellular energy homeostasis. AMPK activity has 
been recently linked to stress resistance and survival in tumor cells (Jeon et al., 
2012; Liu et al., 2012).  
Since AMPK was reported to activate transcription through direct association with 
chromatin and phosphorylation of histone H2B at serine 36, we asked whether the 
AMPK signaling pathway is also involved in the stress-induced loss of H2Bub1 
(Bungard et al., 2010). In order to address this question we tested whether known 
activators for AMPK can influence global H2Bub1 levels. For the stimulation of the 
AMPK activity, two different reagents were used: Metformin, a glucose-lowering drug 
which is in clinical use for the treatment of type 2 diabetes; and AICAR (Acadesine), 
an analog of adenosine (Webster et al., 2010). Changes in AICAR levels in cancer 
cells alter cellular energy level and increases AMPK-dependent glucose uptake and 
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4.3.2.1 AICAR treatment leads to loss of H2Bub1 levels 
Time course experiments with AICAR in H1299 cells revealed a dramatic reduction of 
H2Bub1 levels as early as 30 min and 1 h after AICAR treatment. The level of 
H2Bub1 recovered during the subsequent observation period of up to 24 h. These 
data indicate again that H2B ubiquitination and deubiquitination are very fast and 
highly dynamic processes (Fig. 21A). Surprisingly, Metformin treatment did not 
appreciably affect H2Bub1 levels (Fig. 21B). This leads to the hypothesis that AICAR-
induced loss of H2Bub1 levels is not dependent on AMPK activity per se.  
 
Fig. 21: AICAR treatment but not Metformin leads to reduced H2Bub1 levels.  H1299 cells were 
treated either with 2.5 mM AICAR (A) or 2.5 mM Metformin (B) for the indicated times. H2Bub1 protein 
levels were analyzed by Western blotting using specific antibody against the H2Bub1. H2B served as 
loading control.  
 
4.3.2.2 The effect of upstream kinases on H2Bub1 level 
To further investigate the mechanisms that regulate H2Bub1 levels we determined 
whether the effects of AICAR are mediated by AMPK. Therefore we performed 
siRNA-mediated depletion of AMPK1 and/or AMPK2 and analyzed the level of 
H2Bub1 upon AICAR treatment in whole protein extracts by Western blot. Figure 22A 
shows that AICAR treatment leads to reduced global H2Bub1 protein levels but 
siRNAs targeted to AMPK1 and AMPK2 or a mixture of both do not increase the 
down-regulated H2Bub1 levels upon treatment compared to control siRNA 














AMPK1 antibody in Western blot analysis. Unfortunately, it was not possible to 
check the activation of AMPK by using phospho-AMPK antibody, as no clear signal 
was detectable.  
The tumor suppressor LKB1 is an important upstream serine/threonine kinase that 
phosphorylates and activates the AMPK complex (Hawley et al., 2003). Although 
AMPK activation is lost when LKB1 expression is silenced, the basal activity of AMPK 
remains intact (Hawley et al., 2003). Cells lacking LKB1 display defective energy-
dependent AMPK activation (Shaw et al., 2004). Similar to the results of the AMPK-
knockdown experiment, H2Bub1 levels are decreased upon AICAR treatment but no 
remarkable increase in H2Bub1 was detectable upon siRNA-mediated knockdown of 
LKB1 compared to control-transfected cells in the presence or absence of AICAR 
(Fig. 22B).  
 
Fig. 22: LKB1 and AMPK depletion don`t affect the H2Bub1 level. (A) MCF10A cells were reverse-
transfected with 30 pmol control, AMPK1, AMPK2 or combined  AMPK1+2 siRNA for 72 h 
followed by 2.5 mM AICAR treatment for 30 min. Protein levels were analyzed  by Western blot using 
specific antibody against H2Bub1, AMPK1 and H2B as a loading control. (B) MCF10 and H1299 
cells were transfected with siRNA to LKB1 and treated with 2.5 mM AICAR for 30 min. H2Bub1 protein 
levels were analyzed by Western blotting using specific antibody against H2Bub1. H2B served as 
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Summing up, these data indicate that the loss of H2Bub1 levels upon treatment of 
different stress-inducing factors might be less due to changes in AMPK levels and 
more due to other AMP signaling events. 
4.3.2.3 Effect of AICAR on RNF20 and RNF40 target gene transcription 
Therefore we addressed the question how AICAR-induced H2Bub1 levels are 
regulated. Based on the AICAR dosage course shown in figure 21A all following 
experiments were performed using AICAR treatment for 30 min in order to assure 
efficient reduction in H2Bub1.  
First, we examined whether AICAR treatment changes expression of RNF20 and 
RNF40 dependent genes. Similar as shown above for Actinomycin D and Cisplatin, 
AICAR treatment also led to a decrease in the mRNA levels of the FST, ABCC2 and 
IL1B genes, but not the control gene RPLP0 (figure 23A).  
 
Fig. 23: AICAR treatment leads to reduced RNF20 and RNF40 target gene expression. (A) 
MCF10A cells were treated with 2.5 mM AICAR for 6 h. mRNA levels were analyzed by qRT-PCR. 
Gene expression was normalized to RPLP0 expression (indicated as “Relative mRNA expression”) 
Mean ±SD, n = 3. (B) MCF10A cells were treated with 2.5 mM AICAR for 30 min. mRNA levels were 
analyzed by qRT-PCR. The expression levels were normalized to hnRPLP0. Statistically significant 
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In order to test whether the observed effects on mRNA expression levels of 
RNF20/RNF40 target genes is transcriptional, and if the weak effects shown in figure 
23, e.g. for FST become more apparent we looked for hnRNA expression using hn 
primers, which spans exon-intron boundaries. We observed an even more efficient 
decrease in IL1B and FST hnRNA levels upon AICAR treatment, whereas the RPLP0 
control gene remained unaffected (Fig. 23B). 
4.3.2.4 AICAR affects H2Bub1 occupancy of RNF20/RNF40 target genes 
We next performed ChIP analysis to examine if the effects of AICAR treatment on 
RNF20 and RNF40 target gene expression correlate with decreased H2Bub1 
occupancy levels on these genes. In case of the three representative genes ABCC2, 
IL1B, FST and RPLP0 and GAPDH as control genes, we could observe a clear 
correlation between H2Bub1 occupancy and expression levels of RNF20 and RNF40 
target genes. AICAR treatment resulted in a decreased H2Bub1 occupancy on all five 
genes either at the transcriptional start site (TSS) or the transcribed region (TR) (Fig. 
24). The control genes GAPDH and RPLP0 were not affected in gene expression 
experiments so it could be argued that high H2Bub1 levels are maintained on those 
genes upon AICAR treatment, despite a drop in overall H2Bub1 shown by ChIP data. 
Taken together these results examined that all genes independent of their 
transcriptional response to RNF20 and RNF40 depletion, exhibited a significant 





Fig. 24: H2Bub1 levels decrease upon AICAR treatment.  MCF10A cells were treated with AICAR 
for 30 min. Chromatin extracts were analyzed by ChIP for presence of H2Bub1. IgG antibody was 
used to determine background binding (indicated as dotted line). H2Bub1 occupancy was normalized 
to input (indicated as “% of input”). Mean  SD, n = 3.  
 
4.3.2.5 Involvement of the glucose metabolism in regulating global H2Bub1 
levels 
Stressful conditions deplete ATP stores and increase AMP content in cells. AMPK is 
activated in an AMP-dependent manner and increased AMPK activity results in the 






























































































changes of ATP production in stress-induced enzymatic reactions upon glucose 
starvation and in glucose starvation combined with 2-Deoxy-D-Glucose (2-DG) 
treatment, an ATP determination kit was used. The bioluminescence assay is based 
on luciferase’s requirement for ATP to produce light. 2-DG is a specific blocker for 
glycolysis without altering other nutrients or metabolic pathways and its 
phosphorylation leads to depletion in cellular ATP. In addition, 2-DG is reported to 
activate AMPK (Wang et al., 2011). 
The analysis of the ATP assay revealed that glucose starvation itself already leads to 
a reduction in the intracellular ATP production (Fig. 25A). 2-Deoxy-glucose treated 
MCF10A cells grown in glucose-free medium showed a ten-fold down-regulation of 
cellular ATP levels compared to the control and a five-fold decrease compared to 
glucose starved MCF10A cells. Next, we examined the effect of 2-DG treatment on 
H2Bub1 protein level and indeed we could observe reduced H2Bub1 levels 
compared to control and to glucose starved MCF10A cells (Fig. 25B). 
 
Fig. 25: The glucose metabolism is involved in the regulation of the H2Bub1 level. (A) Detection 
of ATP using the ATP determination kit. Each reaction contained 1.25 μg/mL of firefly luciferase, 50 
μM D -luciferin and 1 mM DTT in 1X Reaction Buffer.  After 5 min incubation, luminescence was 
measured using a Turner Lumiometer. The amount of ATP in the experimental samples was 
calculated from the standard curve. (B) MCF10A cell were seeded in a 6-well plate. After 24 h medium 
was changed to glucose-free medium and cells were treated with either 5 mM or 10 mM 2-Deoxy-












































All these observations suggest that the glucose metabolism is involved in the 
regulation of H2Bub1. This hypothesis is consistent with a previous report showing 
glucose metabolism is required for glucose-induced monoubiquitination of H2B in 
cultured glioma cells (Gao and Xu, 2011). 
 
4.4 H2Bub1 levels are reduced due to the activation of a cellular 
deubiquitinating enzyme 
H2B monoubiquitination is highly dynamic and its level is not only regulated by 
addition, but also by active removal of the ubiquitin residue from the chromatin. Since 
the loss of H2Bub1 following cellular stress happens very rapidly, we questioned 
whether the activity of deubiquitinating enzymes (DUBs) is responsible for the rapid 
decrease of H2Bub1 levels following cellular stress.  
4.4.1 In vitro deubiquitination assay showed increased deubiquitinating activity 
upon treatment with stress-inducing factors 
To examine if the loss of H2Bub1 is primarily caused by decreased ubiquitination or 
whether a specific DUB activity is increased an in vitro deubiqutination assay was 
performed (Fig. 26A). In order to test this protein extracts from normal cells 
(substrate) were mixed with extracts from cells where RNF20 and RNF40 were 
depleted with siRNA to minimize the level of H2Bub1 (effector). When the AICAR- or 
Doxorubicin-treated cells were used for the effector extract the amount of H2Bub1 
was unaffected after 5 min of incubation but after 15 min a decreased H2Bub1 
protein level compared to the non-treated control effector cells was observed, 






Fig. 26: An H2B deubiquitinating activity is increased during cellular stress. (A) Scheme of the in 
vitro deubiquitination experiment (Shchebet, 2011). For details see “Materials and methods”. (B) 
MCF10A cells were transfected with control, RNF20 or RNF40 siRNA and treated with 7.5 μM 
Doxorubicin for 3.5 h or 2.5 mM AICAR for 30 min prior harvesting and performing in vitro 
deubiquitination assay. Protein lysates were analyzed by Western blotting with antibodies specific for 
H2Bub1 and H2B, the latter used as a loading control. 
 
In order to prove that the loss of ubiquitination caused by the presence of the AICAR-
or Doxorubicin-induced effector extract was provided by DUBs, we performed 
another in vitro deubiquitination experiment. Therefore co-immunoprecipitations (Co-
IP) with ATXN7L3 or USP22 overexpression constructs were performed but the 
subsequent in vitro deubiquitination assay with synthesized nucleosomes did not 
provide conclusive data (data not shown). 
4.4.2 The SAGA complex is required for H2B deubiquitination 
In mammalian cells the deubiquitinating enzyme module (DUBm) for H2Bub1 is 
incorporated into the SAGA complex that also exhibits histone acetylation. USP22 
(ubiquitin specific protein) is a deubiquitinating enzyme that has been shown to 
deubiquitinate nucleosomes containing H2Bub1 in vitro. Recently, a report showed 
that USP22 is allosterically regulated by interactions with different domains of other 
DUB module subunits, namely ATXN7, ATXN7L3, and ENY2. Consistently, 
knockdown of the core DUBm component ATXN7L3 led to a significant increase in 
H2Bub1 (Lang, 2011). To study the importance of deubiquitination in stress-induced 
Effector
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loss of H2Bub1 the effect of depletion of the SAGA DUBm complex components 
USP22, ATXN7L3, ATXN7 and ENY2 was analyzed in MCF10 cells. 
4.4.2.1 USP22 is needed for the stress-induced deubiquitination  
We hypothesized that the activity of USP22 could be crucial for the stress-induced 
reduction of H2Bub1. As shown in figure 23A, Actinomycin D treatment leads to 
reduced global H2Bub1 levels. Western blot analysis revealed that siRNA-mediated 
knockdown of USP22 in MCF10A cells increases H2Bub1 levels upon Actinomycin D 
treatment compared to control-siRNA transfected Actinomycin D treated cells. 
qRT-PCR experiments were performed to determine whether USP22 knockdown is 
capable of rescuing the effects of Actinomycin D treatment on RNF20/RNF40-
dependent genes. Indeed siRNA-mediated knockdown of the deubiquitinating 
enzyme USP22 restore the decreased gene expression level of the target genes 





Fig. 27: USP22 regulates the level of H2Bub1. (A) MCF10A cells were transfected with siRNA 
against USP22. After 72 h cells were treated with 20 nM of Actinomycin D for 3 h. Extracts were 
analyzed by Western blot. (B) MCF10 cells were reverse-transfected with 30 pmol control or USP22 
siRNA for 72 h and treated with Actinomycin D for 3 h. Isolated RNA was reverse-transcribed with 
random primers and analyzed by qPCR. Target gene expression levels were normalized to RPLP0, 
graphed relative to the control-transfected sample and expressed as “relative mRNA expression”. 
Statistically significant differences are indicated: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; mean ±SD, n = 3. 
 
To further determine if these effects could be reproduced via Cisplatin treatment, 
Western blot analyses were performed with different concentrations of the DNA-
damaging drug. As shown in figure 24 siRNA targeted to USP22 efficiently rescues 
H2Bub in both MCF10A (Fig. 28A) and H1299 (Fig. 28B) cells at various 
concentrations. However, at high concentrations such as 50 M Cisplatin the loss of 
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Fig. 28: USP22 is needed for Cisplatin-mediated reduction of H2Bub1. MCF10A (A) and H1299 
(B) cells were transfected with siRNA against USP22. After 60 h cells were treated with indicated 
concentrations Cisplatin for 12 h. Protein extracts were analyzed by Western blot using the indicated 
antibodies. 
 
Gene expression studies shown in figure 29 demonstrated again a decrease in 
ABCC2, FST and IL1B mRNA level upon Cisplatin treatment. The mRNA expression 
levels of the RNF20/RNF40-dependent genes upon USP22 depletion in the presence 
of Cisplatin were elevated compared to the non-transfected Cisplatin treated control 
but only ABCC2 showed a significant increase in gene expression level which was 
comparable to the non-transfected control.  
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Fig. 29: RNF20 and RNF40 target gene expression upon Cisplatin treatment and USP22 
knockdown.  MCF10 cells were reverse-transfected with 30 pmol control or USP22 siRNA for 60 h 
and treated with Cisplatin for 12 h. Isolated RNA was reverse-transcribed with random primers and 
analyzed by qRT-PCR. Target gene expression levels were normalized to RPLP0, graphed relative to 
the control-transfected sample and expressed as “relative mRNA expression”. Statistically significant 
differences are indicated: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; mean ±SD, n = 3. 
 
In order to investigate a possible genome-wide role for SAGA deubiquitination activity 
on H2Bub1 the effect of siRNA-mediated knockdown of USP22 on the H2Bub1 
occupancy in MCF10A cells was analyzed by ChIP experiments. ChIP analysis 
revealed that H2Bub1 levels are general lower at the TSS compared to the TR 
region. In fact, our data showed that when SAGA deubiquitination activity is impaired 
by USP22 knockdown the H2Bub1 levels in MCF10A cells were strikingly increased 
in the three RNF20/RNF40-dependent genes and the control genes (Fig. 30). 
Importantly, the results of this ChIP analysis confirm the observed rescue of the 
H2Bub1 levels in Western blot and mRNA gene expression for all tested genes, since 
a significant increase in H2Bub1 occupancy was observed in Cisplatin treated USP22 
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These results imply that USP22 DUB activity is a major regulator of this modification 
and cannot be fully compensated by other deubiquitinases. 
 
 
Fig. 30: Regulation of RNF20 and RNF40 target gene expression correlates with H2Bub1 
occupancy upon Cisplatin treatment and USP22 knockdown. MCF10 cells were treated as 
described in Fig. 25. Chromatin extracts were analyzed by ChIP for presence of H2Bub1. IgG antibody 
was used to determine background binding (indicated as dotted line). H2Bub1 occupancy was 
normalized to input (indicated as “% of input”). Statistically significant differences are indicated: *P ≤ 
0.05; **P ≤ 0.01; ***P ≤ 0.001; mean ±SD, n = 3.  
 
4.4.2.2 Chemotherapeutical treatment also affects H2A ubiquitination 
Several studies indicated that in addition to H2B, USP22 deubiquitinates H2A in vitro 
(Zhao et al., 2008). Therefore, we sought to determine if the DNA-damaging drug 
Cisplatin has a similar effect on H2Aub1 levels. Indeed, treatment with Cisplatin 
resulted in a decrease in the H2Aub1 protein level which is comparable to that of 
H2Bub1 as depicted in figure 31. Nevertheless, USP22 knockdown did not 































































































































































































































































to control siRNA transfected Cisplatin treated cells indicating that activity of USP22 is 
not crucial for the stress-induced reduction of H2Aub1 levels. 
 
Fig. 31: Cisplatin treatment affects H2A ubiquitination. MCF10A cells were transfected with siRNA 
against USP22. After 60 h cells were treated with indicated concentrations of Cisplatin for 12 h. 
Protein extracts were analyzed by Western blot using H2Aub1 and H2Bub1 antibodies. The efficient 
knockdown is shown by immunoblotting using USP22 antibody and -actin antibody was used as a 
control. 
 
4.4.2.3 Depletion of SAGA DUB module components leads to H2Bub1 
accumulation  
To test whether depletion of SAGA DUBm components leads to increased H2Bub1 
levels following the induction of cell stress MCF10A cells were transfected with 
siRNA to ATXN7L3, ATXN7 and ENY2 for 72 h. Western blot analysis confirmed a 
decrease in H2Bub1 level upon Cisplatin and AICAR treatment and a potent increase 
in H2Bub1 upon ATXN7L3 depletion either in control or in treated cells. siRNA 
mediated knockdown of ATXN7L3 showed the strongest up regulation of H2Bub1 
uder both, normal and stress-induced conditions, but ATXN7 and ENY2 knockdown 
also increased H2Bub1 levels upon knockdown compared to non-transfected control 
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Fig. 32: Knockdown of SAGA DUBm subunits reverses stress-induced loss of H2Bub1 levels.  
MCF10A cells were reverse-transfected with 30 pmol control, ATXN7L3, ATXN7, and ENY2 siRNA for 
48 h followed by treatment with either 50 M Cisplatin or 2.5 mM AICAR for 30 min. H2Bub1 protein 
levels were analyzed by Western blot using specific antibodies against H2Bub1 and H2B as a loading 
control. 
 
To further test this results gene expression analysis upon siRNA-mediated 
knockdown of ATXN7L3, ENY2 and USP22 was examined in MCF10A cells. Cells 
were transfected with the indicated siRNAs followed by AICAR treatment for 30 min 
and gene expression analyses by qRT-PCR. These data confirm observations from 
the Western blot. First of all, the efficient knockdown of ATXN7L3, ENY2 and USP22 
was confirmed on mRNA levels (Fig. 33). Interestingly, ATXN7L3 knockdown 
resulted in an increased ENY2 mRNA level but not vice versa indicating that 
ATXN7L3 expression is possibly crucial for the full activity of the DUBm and depletion 
of it may need to be compensated by up-regulation of one of its interacting 
components. For FST gene AICAR decreased mRNA expression levels can be 
rescued upon ATXN7L3 depletion. During this experiment IL1B do not show any 
significant changes in gene expression level upon ACIAR treatment or knockdown of 
any DUBm component. ABCC2 mRNA level is rescued in USP22 depleted MCF10A 
cells, but not significantly upon ENY2 and ATXN7L3 knockdown. RPLP0 was used 
as a control and was unaffected upon treatment and siRNA-mediated knockdown. 











Fig. 33: DUB module components are needed for AICAR-mediated rescue of H2Bub1. MCF10A 
cells were transfected with siRNA against ATXN7L3, ENY2 and USP22. After 72 h cells were treated 
with 2.5 mM AICAR for 30 min. RNA was isolated and cDNA was analysed by qRT-PCR using hn 
primers. Gene expression was normalized to hnRPLP0 expression (indicated as “relative mRNA 
expression“).  hn – heterogeneous nuclear. Statistically significant differences are indicated: *P ≤ 0.05; 
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To check whether H2Bub1 is also increased on RNF20 and RNF40 dependent genes 
its occupancy was examined by ChIP with corresponding antibodies (Fig. 34). Both 
RNF20 and RNF40 regulated genes, ABCC2 and FST, demonstrated decreased 
H2Bub1 occupancy upon AICAR treatment on TSS and TR and an increased 
H2Bub1 occupancy on both regions upon ATXN7L3 depletion. Interestingly, RPLP0, 
used as a RNF20 and RNF40 independent gene, also possessed lower H2Bub1 
levels in AICAR-treated MCF10A cell and high levels of H2Bub1 after ATXN7L3 
knockdown.  
 
Fig. 34: Correlation of RNF20 and RNF40 target gene expression and H2Bub1 occupancy upon 
AICAR treatment and ATXN7L3 knockdown. MCF10A cells were transfected with siRNA to 
ATXN7L3 for 72 h and treated with AICAR for 30 min. Chromatin extracts were analyzed by ChIP for 
presence of H2Bub1. IgG antibody was used to determine background binding (indicated as dotted 
line). H2Bub1 occupancy was normalized to input (indicated as “% of input”). Statistically significant 
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This observation suggests that induction of stress leads to a genome-wide H2Bub1 
reduction and inactivation of the SAGA DUB module component results in an 
accumulation of H2Bub1. Thus, H2Bub1 occupancy in AICAR treated ATXN7L3 
depleted cells compared to control siRNA- and AICAR- treated cells was significantly 
increased on all examined genes. 
 
Fig. 35: RNAPII recruitment upon AICAR treatment and ATXN7L3 knockdown.  MCF10A cells 
were transfected with siRNA to ATXN7L3 for 72 h and treated with AICAR for 30 min. Chromatin 
extracts were analyzed by ChIP for presence of RNAPII. IgG antibody was used to determine 
background binding (indicated as dotted line). RNAPII occupancy was normalized to input (indicated 
as “% of input”). Statistically significant differences are indicated: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; 
mean ±SD, n = 3.  
 
H2Bub1 is associated with the transcribed regions of active genes and may promote 
active transcription. We carried out ChIP analyses with an RNAPII antibody, which 
recognizes both the phosphorylated and unphosphorylated forms of the RNAPII and 
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knockdown affect the recruitment of RNAPII to RNF20 and RNF40 target genes. 
ATXN7L3 knockdown did not appreciably affect elongation at the transcribed region 
of RPLP0. As shown in figure 35A AICAR treatment leads to decreased elongating 
RNAPII levels at the transcriptional start site. The amount of total RNAPII at the TSS 
of FST and ABCC2 was decreased to less than 50% upon AICAR treatment. 
ATXN7L3 depletion led to increased recruitment of RNAPII independently of AICAR 
treatment for FST (Fig. 35B). The results confirm the observed rescue upon 
ATXN7L3 knockdown and AICAR treatment on FST gene expression level (Fig. 34) 
and suggest that up-regulated H2Bub1 levels upon ATXN7L3 knockdown facilitate 
transcriptional elongation even in the presence of stress-inducing factors. For ABCC2 
the amount of elongating RNAPII in ATXN7L3 depleted cells in the presence or 
absence of AICAR do not change compared to AICAR treated control-transfected 
cells. This could be because ABCC2 gene is unable to rescue AICAR-mediated loss 
of H2Bub1, since gene expression analysis showed the same result (data not 
shown). 
 
4.5 Genome-wide analysis of H2Bub1 distribution 
To better understand H2Bub1 function we carried out genome-wide analysis of 
H2Bub1 distribution in MCF10A cells. Chromatin immunoprecipitation followed by 
DNA sequencing (ChIP-Seq) allows genome-wide discovery of protein-DNA 
interactions and provides insight into the function of histone modifications and 
chromatin structure (Park, 2009; Robertson et al., 2007).  
4.5.1 ChIP-seq analyses show H2Bub1 occupancy and its changes upon 
ATXN7L3 knockdown 
Histone H3 lysine 4 monomethylation (H3K4me) and trimethylation (H3K4me3) as 
well as hyperacetylation of histone H3 and H4 are known as active marks and are 
associated with transcriptional initiation and elongation (Heintzman and Ren, 2009; 
Wang et al., 2008). Thus, downloaded and analyzed data from the public database 
European Nucleotide Archive against H3K4me1, H3K9/14ac and H3K4me3 in 




and distribution profiles can be compared with our data of H2Bub1. To analyze our 
data the sample duplicates for H2Bub1 were merged after mapping and then WIG 
files which contain a continuous ChIP enrichment signal were identified by the peak-
caller MACS (Model-based Analysis of ChIP-seq) using normalization to input (Zhang 
et al., 2008b). In our ChIP-seq experiment we used a highly specific antibody 
recognizing H2Bub1 and confirmed that H2Bub1 is mostly associated with the 
transcribed region of expressed genes. Consistent with other recently published 
papers, H2Bub1 demonstrated relatively strong signals near the 5’ regions of many 
actively transcribed genes (Jung et al., 2012; Minsky et al., 2008; Vethantham et al., 
2012). Data for H3K4me3 and H3ac correlate quantitatively and showed an 
enrichment in the regions surrounding the transcriptional start sites (TSS) especially 
downstream as previously reported in human cells (Barski et al., 2007; Jung et al., 
2012; Wang et al., 2008).  
Up to date, the genome-wide recruitment of the SAGA DUBm and the sites where 
SAGA deubiquitinates H2B have not been established. ChIP-seq data confirmed the 
observed increase in H2Bub1 following ATXN7L3 knockdown but the H2Bub1 
enrichment does occur uniform across genes, but rather at specific sites primarily 
towards the 5' end. Figure 36A shows the housekeeping genes GAPDH and ACTB 
which are expressed at relatively constant levels in most situations and HNRNPK, a 
major pre-mRNA-binding protein that was unaffected in our microarray of RNF20 and 
RNF40 depleted MCF10A cells and was not regulated upon 17ß-Estradiol treatment 





























































Fig. 36: ChIP-seq profile of different histone marks. Genome browser tracks depicting H3K4me1, 
H3K9/14ac, H3K4me3 in control MCF10A cells as well as H2Bub1 of control- and ATXN7L3-siRNA 
transfected MCF10A cells ChIP-seq peaks at representative gene loci. (A) Control genes which are 
usually highly expressed in cells. (B) Representative data of very highly expressed genes in MCF10A 
according to our microarray data. 
 
However, generally our data demonstrated an increase in H2Bub1 level upon 
ATXN7L3 knockdown but not across the whole gene body. For example, on the 
GAPDH gene there is a significant increase on the second exon. The ACTB gene 
looks very similar where exon two again shows nearly a doubling of H2Bub1 in 
ATXN7L3 depleted MCF10A cells and the peak upstream of that also increases at 







































increase is on the second intron. The regions after that show some changes as well, 
but not nearly as much as close to the 5’ end of the gene. Furthermore a new peak 
from around the 5’ end was visible too. Two very highly expressed genes according 
to our microarray data are depicted in figure 36B. For TPT1 the peak near the 5’ end 
is nearly non-existent until ATXN7L3 knockdown. On MT2A the effects is also clear. 
This gene is quite small though, so that the increase on the second and third introns 
is also still fairly TSS proximal and overlaps significantly with H3K4me3. Interestingly, 
the two peaks in the right part of the figure do not go up, but rather down following 
ATXN7L3 knockdown, again pointing to the specificity of the effect for the position on 
the given gene. In most cases a significant change in H2Bub1 levels upon ATXN7L3 
knockdown appears to be at the 5’ end of the gene. The results of our ChIP data 
suggest a gene-specific role for SAGA deubiquitination activity on H2Bub1 since 
ATXN7L3 knockdown increases H2Bub1 levels in the transcribed region of 
expressed genes. 
All together these data reveal that H2Bub1 does not cover the whole transcribed 
region as previously thought, and the increase of H2Bub1 following ATXN7L3 
knockdown is rather visible at specific locations in a gene dependent manner. 
4.5.2 Genome-wide averages of the H2Bub1 profile based on gene expression 
level 
In order to visualize signal enrichment around the transcriptional start site (TSS), in 
the gene body and at the transcription terminating site (TTS) we generated average 
ChIP signal profiles of H2Bub1 in control and ATXN7L3 depleted MCF10A cells 
around these genomic features. The metagene profiles were plotted using CEAS 
(Cis-regulatory Element Annotation System), a tool designed to characterize 
genome-wide protein-DNA interaction patterns from ChIP-chip and ChIP-seq (Ji et 
al., 2006). The genes were sorted into four quartiles according to gene expression 
level in control MCF10A cells (data obtained by our microarray). Generation of four 
sub-groups, 1st quartile (highest expression level), the 2nd quartile (medium to highly 
expressed), the 3rd quartile (medium to lowly expressed) and the 4th quartile (lowly or 






Fig. 37: Average ChIP enrichment signal around TSS, in gene body and around TTS of genes. 
The red (Q1), pink (Q2), green (Q3) and  blue (Q4) colors indicate the average ChIP enrichment 
signals of the 1
st
 quartile (highest expression level), the 2
nd
 quartile (medium to highly expressed), the 
3
rd
 quartile (medium to lowly expressed) and the 4
th
 quartile (lowly or not  expressed) of the expressed 
genes, and black displays all RefSeq genes. The solid lines represent control and the striped lines 
ATXN7L3 knockdown samples. The average signal is drawn around the transcriptional start site (TSS) 
and the transcription terminating site (TTS) aligning all 5' ends and all 3' ends. 
 
Figure 37 represents the average ChIP signal along the gene with aligned 5' ends 
and 3' ends and shows that H2Bub1 in control MCF10A cells is low at the TSS, 
enriched in gene bodies and stays nearly constant towards the 3’ end where it finally 
decreases. There is no clear correlation between gene expression level and H2Bub1 
profile in control cells. In addition, it was observed that upon ATXN7L3 knockdown 
H2Bub1 is highly increased downstream of the TSS but is not changed at the TTS 
compared to control siRNA treated cells. This effect is clearly dependent on the gene 
expression level. The average ChIP signal of the 1st quartile (Q1) shows the highest 
increase upon ATXN7L3 knockdown, compared to control cells. The 2nd quartile is 
lower than the 3rd quartile (Q3) and the 4th quartile (Q4) is lower than the 3rd quartile 
showing expression-dependent increase following ATXN7L3 knockdown. 
Out of these result we can speculate that average H2Bub1 does not necessarily 
correlate with gene expression but rather that the dynamic ubiquitination and 






















Chromatin structure and histone modifications have been associated with gene 
transcription which is tightly regulated by transcription factors and epigenetic factors 
that control accessibility of the chromatin (Berger, 2007). As more is learned about 
transcriptional regulation, the ability to gain insight into a cell’s response to 
physiological signals or external stimuli will become increasingly powerful. Genome-
wide analysis of histone H2B monoubiquitination (H2Bub1) distribution revealed a 
preferred association with actively transcribed genes in mammalian cells (Minsky et 
al., 2008). H2Bub1 levels were shown to start near the transcriptional start site with a 
gradually increase into the transcribed region (Minsky et al., 2008). Recently 
published data including our results demonstrate a 5’ bias for H2Bub1 (Jung et al., 
2012; Vethantham et al., 2012). Despite this, little is known about the dynamics of 
H2B monoubiquitination under different physiological conditions. Our goal was to 
gain insight into mechanisms of stress-induced H2B deubiquitination and the role of 
H2B monoubiquitination during tumorigenesis and metastasis. 
 
5.1 The role of H2Bub1 as a potential tumor suppressor 
5.1.1 Function of RNF20 and RNF40 in cellular responses 
One way to assess the function of H2B monoubiquitination is to deplete or to 
overexpress the corresponding E3-ligase components and to test the functional 
consequences. This was analyzed in the current study for the putative ubiquitin 
ligases RNF20 and RNF40 within a physiological cellular context. The observed anti-
proliferative effects of siRNA-mediated knockdown of RNF20 or RNF40 on cell cycle 
progression as well as after RNF40 overexpression suggest that misregulation of the 
H2Bub1 machinery is tightly linked to cell proliferation. A dominant negative effect 
could explain the same outcome of RNF40 knockdown as well as its overexpression. 
For instance unphysiologically high RNF40 overexpression could lead to partial 
functional inactivation of RNF40 but may not prevent formation of the heterodimer 
with RNF20. It is known that RNF20 and RNF40 form a complex in vivo and both are 




al., 2009a). Thus, RNF40 could possibly bear a dominant negative effect on RNF20. 
When RNF40 as a monomer binds to a different partner and thus prevents the 
interaction partner to carry out its dimer function, inactivation of this protein complex 
would be the consequence. For example, RNF40 binds to WAC which is known to 
recruit the RNF20/RNF40 complex to the chromatin, inhibiting the ability of WAC to 
bind to its true target and is therefore getting inactive.  
Triggered by the growth inhibitory effects of RNF40 knockdown observed in the 
current study and by the previously published significant increase in cellular migration 
upon depletion of RNF20 (Shema et al. (2008)), we decided to perform in vitro 
migration assays and showed increased migratory potential of the normal mammary 
epithelial cell line MCF10A upon either RNF20 or RNF40 knockdown. Enhanced cell 
migration is a pronounced feature of advanced tumors and therefore decreased 
RNF20 and RNF40 expression may potentially facilitate cancer progression. Both cell 
proliferation and cell migration are crucial to a variety of physiological and 
pathological processes. The decision of a cell to either proliferate or migrate relies on 
the balance of many stimulatory and inhibitory control molecules and factors. From in 
vitro studies it appears that cell proliferation and cell migration are mutually exclusive 
(Farin et al., 2006; Zheng et al., 2009). The mutual exclusiveness of proliferation and 
migration may explain why upon RNF20 and RNF40 knockdown the cells display 
both decreased proliferating capacity and increased migratory potential. Invasive 
cancer cells can proliferate but may not do so while actively moving. This is 
consistent with the observation that cells usually stop moving while dividing and then 
may migrate again. Our data showing growth inhibition and increased migration upon 
RNF20 and RNF40 depletion raises the question whether inhibition of H2Bub1 would 
be a benefit or a disadvantage for tumor therapy. Initiation of metastasis is 
associated with an EMT (extravasation). Carcinoma cells in primary tumors lose cell-
cell adhesion and enter the bloodstream. To form metastases the circulating tumor 
cells (CTCs) must invade the target organ (intravasation) and then undergo an MET 
(mesenchymal-epithelial transition) for clonal outgrowth (Chaffer and Weinberg, 
2011). This model suggests that therapeutic inhibition of H2Bub1 should be given 
constantly because spreading of cells is dispensable if cells stop proliferating. 




metastasis. In contrast, our immunohistochemical analyses of H2Bub1 expression in 
metastases revealed that colonization is H2Bub1-independent since no levels of 
H2Bub1 could be observed in metastasis tissue microarrays. This suggests that 
additional pathways may be activated during tumor metastases which overcome a 
need for H2Bub1 in order to undergo MET. Taken together these findings support the 
hypothesis that the RNF20/RNF40 complex has a tumor suppressor function 
probably through its regulation of H2Bub1. This could have interesting implications 
for therapeutic treatment. 
RNF20 suppresses the expression of several proto-oncogenes (Shema et al., 2008). 
Furthermore, the results of a recent study showed a highly methylated CpG island in 
the promoter of the RNF20 gene in human breast tumors in comparison to normal 
tissues which reduces RNF20 gene expression (Shema et al., 2008) indicating that 
during tumor progression the expression of the potential tumor suppressor RNF20 
may be inhibited by promoter hypermethylation. A question that arises from these 
observations is whether H2Bub1 accumulation correlates with malignancy. A support 
for this hypothesis is revealed from our studies on the expression levels of H2Bub1 in 
primary colon (this study) and breast (Prenzel et al., 2011) tumor samples, which 
showed a correlation of H2Bub1 loss with tumor progression. 
Thus, a loss of H2Bub1 levels during tumor progression may be a potentially therapy-
relevant finding. To confirm this hypothesis immunohistochemical studies directly 
investigating the levels of H2Bub1 in different tumor types and stages, will be 
important in determining whether loss of H2Bub1 is a general effect occurring during 
tumor progression. To gain more knowledge on the underlying molecular 
mechanisms of the function of H2Bub1 and its ubiquitin ligases in cancer, 
establishment of new conditional mouse knockout models of RNF20 and RNF40 will 
be necessary to determine the effects of genetic ablation of these genes on tumor 
initiation and progression in various tumor models. Furthermore, in vitro experiments 
and in vivo xenograft transplantation experiments may reveal additional insights into 





5.1.2 RNF20 and RNF40 modulated gene expression 
In the current study a more global overview of the transcriptional effect upon 
extensive reduction of H2Bub1 via RNF20 and RNF40 depletion was obtained 
through mRNA expression profiling in MCF10A cells for a total of 11,223 genes. The 
microarray analysis revealed that the expression of RNF20 and RNF40, probably 
through H2Bub1, activates or suppresses distinct gene classes. Consistent with 
earlier observations in yeast (Mutiu et al., 2007; Tanny et al., 2007) and similar to a 
recent genome-wide study using RNF20 depleted HeLa cells (Shema et al., 2008), 
we found that basal expression of only a small subset of genes significantly depends 
on RNF20 and RNF40.  
It is currently unclear why only a subset of genes is modulated by RNF20 and RNF40 
knockdown. One reason may be that the heterodimeric RNF20/RNF40 complex 
affects the activity of only some transcriptional regulators. The search for specific 
transcription factor motifs located on RNF20/RNF40-regulated genes is one way to 
examine this possibility. Alternatively, only genes located in particular chromatin 
domains may be affected by H2Bub1 and thus clusters of adjacent genes could be 
co-regulated via H2Bub1. Shema et al. (2008) speculated about the function of 
H2Bub1 in maintaining highly inducible genes in a transcriptionally restricted state. 
Accordingly, H2Bub1 may prevent accidental expression of these genes in the 
absence of an activating signal. With its highly dynamic nature H2Bub1 would be 
predisposed for controlling such rapid switches. The loss of the transcription inhibiting 
H2Bub1 mark might suppress the expression of these tightly regulated genes. This 
could be a possible explanation of the more transformed phenotype of cells upon 
RNF20 and RNF40 depletion in vitro.  
Recently published data from our group demonstrated that differentiation-activated 
genes become inhibited and increase their transcription upon RNF40 depletion 
suggesting that absence of H2Bub1 reverses the effect of the differentiation signal. In 
respect to these findings we hypothesized H2Bub1 to be essential for the rapid and 
strong transcriptional activation as it happens during differentiation (Karpiuk et al., 
2012). Another possible explanation was provided by Fuchs et al. 2012 who revealed 




signals. Based on lower basal expression levels of RNF20-dependent longer genes 
one can speculate the requirement of H2Bub1 to switch such genes into a more open 
chromatin state and thus increases overall transcription elongation rate (Fuchs et al., 
2012). 
In contrast to the distribution of H2Bub1 on most active genes, suppression of H2B 
ubiquitination appears to have a mild effect on gene expression. Consistent with 
earlier observations in yeast (Mutiu et al., 2007; Tanny et al., 2007) and similar to a 
recent genome-wide study using RNF20 depleted HeLa cells (Shema et al., 2008), 
we found that only a small subset of genes had an altered expression after depletion 
of the H2B ubiquitination enzymes in human cells. This raises the question why is 
only a subset of genes modulated by RNF20 knockdown? H2Bub1 may, instead of 
directly facilitating transcription elongation could have functions independent of the 
transcription process itself or alternatively RNF20 and RNF40 may affect the activity 
of only some transcriptional regulators.  
Possible mechanistic explanations for the presumed tumor-suppressor activity of 
RNF20 and RNF40 can be offered by the identity of RNF20/RNF40 regulated genes.   
Notably, RNF20 and RNF40 restrain the transcription of genes whose expression 
correlates with malignancy.  
From our microarray we found genes implicated in the IL1B signaling pathway, 
including IL-1β itself and IL1RAP. IL-1β is a pleiotropic pro-inflammatory cytokine and 
is negatively regulated by the ubiquitin ligase complex. IL-1ß is closely associated 
with tumor cell proliferation (Farrow and Evers, 2002; O’Neill, 2000) possibly 
explaining the anti-proliferative effects of RNF20 and RNF40 depleted cells as 
documented in this study. IL-1β forms a complex with an Interleukin-1 receptor 
accessory protein (IL1RAP), which is also repressed upon RNF20 and RNF40 
depletion. The data obtained in these studies are contradictory to increased migratory 
potential of RNF20 and RNF40 depleted MCF10A cells but can be explained by the 
use of a different signaling pathway or tumor type specificity. 
Another tumor-relevant pathway found to be regulated is the activin-signaling 
pathway. Activin signaling has been involved in many physiological processes, 




al., 2001; Woodruff and Mather, 1995). The Follistatin FST gene is a TGF-β 
antagonist found to be down-regulated in an EMT core signature (Taube et al., 2010) 
and displays an additional interesting RNF20/RNF40 target. Both activin and TGF-β 
have anti-proliferative effects on many types of cells, including cancer cells and 
function as tumor suppressors in early stage tumorigenesis (Chen et al., 2006; 
Massagué, 1998). Follistatins mediate cell growth, development, and differentiation in 
various tissues and can block the interaction between activins and their cell-surface 
receptors by binding activin and thus suppress activin signaling activity (Welt et al., 
2002). Follistatin interacts with the activin A receptor ACVR1C, which is up-regulated 
in our microarray experiment and thus possibly explains some of the biological 
effects documented in figures 5, 9 and 13.  
Furthermore, RNF20/RNF40 depletion down-regulates ABCC2 expression (Fig. 12). 
ABCC2 is a multiple organic anion transporter that transports a variety of anticancer 
drugs, including Cisplatin (Cui et al., 1999) and Actinomycin D (Lin et al., 2011). The 
transport of Actinomycin D and Cisplatin by ABCC2 could be therapeutic relevant as 
it potentially alter drug exposure und influence toxicities (Hill et al., 2013). ABCC2 is 
expressed in different tumor cell lines (Narasaki et al., 1997) and in some solid 
tumors (Sandusky et al., 2002). Some Cisplatin- and Doxorubicin-resistant cell lines 
have been reported to have highly increased ABCC2 mRNA levels (Kool et al., 1997; 
Taniguchi et al., 1996).  
Surprisingly, RNF20/RNF40 depletion elevated the expression of the proto-oncogene 
MET in MCF10A cells. c-MET encodes a transmembrane receptor tyrosine kinase, 
that has been involved in tumorigenesis (Naldini et al., 1991). Data of several studies 
obtained that increased MET levels are associated with metastasis and poor 
prognosis (Beviglia et al., 1997; Camp et al., 1999; Ghoussoub et al., 1998). The 
tumorigenic function of MET in vivo remain largely unknown. Overexpressed MET 
proto-oncogene mediates development of metastatic mammary tumors in transgenic 
mice (Jeffers et al., 1998; Liang et al., 1996). The results are in good agreement with 
the observed increase of MET in our microarray and the increased migratory 




While H2Bub1 is required for the expression of some genes, the transcriptional 
suppression effects observed on other genes may be linked to decreased recruitment 
of the transcriptional elongation factor TFIIS to certain proto-oncogenes (Shema et 
al., 2011). The sum of these effects on growth promoting and growth restrictive 
pathways, as well as RNF20- and RNF40-related alterations in human cancer, 
suggest a tumor-suppressor role of H2Bub1 and its ubiquitin ligases RNF20 and 
RNF40 likely through selective modulation of defined subsets of genes by a 
combination of positive and negative transcriptional or posttranscriptional effects. 
5.1.3 Substrate specificity of RNF20 and RNF40 
At present our DNA microarray data raises the concern whether some of the effects 
of RNF20 and RNF40 depletion may involve other, unknown targets of its ubiquitin 
ligase activity. Consistent with this speculation, RNF20 has been shown to target the 
ErbB3-associated protein Ebp1. Ebp1, a putative tumor suppressor protein 
possesses two isoforms, p42 and p48, that demonstrate different binding affinities to 
the ErbB3 receptor (Liu et al., 2006). Surprisingly, p42 but not p48 binds to ErbB3 
receptor which is strongly stimulated by EGF and inhibits cell proliferation and 
induces the differentiation of cancer cells. Moreover, RNF20 polyubiquitinates p42 
resulting in its degradation in human cancers (Liu et al., 2009). These findings open 
the possibility that RNF20/Ebp1 interaction may directly influence EGF-signaling. 
Deficiency of either Ebp1 or RNF20 might lead to increased EGF-signaling and could 
explain the pronounced effects on the expression of key growth-regulating genes 
upon RNF20 depletion (Shema et al., 2008). Thus, increased EGF-signaling due to 
RNF20 depletion and a concomitant decrease in H2Bub1 might explain why 
specifically EGF-regulated genes are affected despite the fact that H2Bub1 is 
distributed on most active genes. Thus, these effects may potentially be independent 
of RNF20 and RNF40 effects on chromatin structure. Similarly to the ubiquitination-
dependent loss of Ebp1 in cancer tissues our data show decreased H2Bub1 in colon 
and breast cancer tissue (Prenzel et al., 2011). However, up to now it is not known, if 
and how RNF40 affects the Ebp1 activity or ubiquitination. 
Staring protein, the rat ortholog of RNF40 was shown to ubiquitinate Syntaxin 1 




additional RNF20/RNF40 substrates is the composition of the heterodimeric complex 
itself. Most metazoans and Schizosaccharomyces pombe require an obligate 
heterodimer for H2B monoubiquitination while Saccharomyces cerevisiae, Drosophila 
melanogaster and Caenorhabditis elegans only appear to have one 
Bre1/RNF20/RNF40 ortholog.  
Moreover, a series of studies showed that while both RNF20 and RNF40 possess an 
intact RING-finger domain, only the RING finger of RNF20 was needed for 
transcription-coupled monoubiquitination of H2B in vitro (Kim et al., 2009). Provided 
the RNF40 RING-finger domain and therefore its ubiquitin ligase activity are not 
essential for global H2Bub1 levels, why is it then evolutionarily conserved? A 
plausible explanation is its requirement for different substrates, possibly independent 
of RNF20. Further protein-protein interaction and mass spectrometry studies are 
necessary to uncover additional substrates of RNF20 and RNF40 and to reveal 
additional insight into the molecular mechanism involved in the biological effects of 
both ubiquitin ligases. 
 
5.2 Stress-induced H2B deubiquitination 
5.2.1 H2Bub1 is strongly reduced by various treatments 
In the course of this study we have demonstrated that the ubiquitination of histone 
H2B is rapidly and strongly reduced upon various treatments such as 
chemotherapeutic drugs (Doxorubicin, Cisplatin), osmotic stress (Sorbitol), heat 
shock and induction of ribosomal stress by Actinomycin D. The DNA-damaging drug 
Doxorubicin decreased H2Bub1 levels at much higher concentrations than needed 
for a DNA-damage response. These findings are not astonishing taken into account 
that recent reports showed that H2Bub1 is induced at DNA damage sites and is 
needed for the proper repair (Kari et al., 2011; Moyal et al., 2011; Nakamura et al., 
2011). Previous research proposed that the loss of H2Bub1 upon treatment with 
inhibitors of transcription and heat shock is because of depletion of free monomeric 
ubiquitin due to insufficient recycling of ubiquitin from polyubiquitinated proteins 




not lead to an accumulation of polyubiquitinated proteins in the cell (Shchebet, 2011) 
and furthermore, Actinomycin D was reported to inhibit the accumulation of 
polyubiquitinated proteins (Ding et al., 2007). Altogether our data show a strong 
reduction of H2Bub1 upon treatment suggesting the existence of an additional 
actively regulated multiple factor-induced H2Bub1 regulating pathway upon stress 
conditions.  
The physiological role of this rapid deubiquitination is not yet clear. Yeast cells can 
rapidly shut off transcription and start the gene expression adapted to the new 
conditions again within 15 min (Miller et al., 2011). In addition, a recent study 
assessed the role of H2Bub1 on expression changes during photomorphogenesis 
that initiates a rapid developmental switch in Arabidopsis thaliana showing the rapid 
and extensive transcriptional reprogramming (Bourbousse et al., 2012). It can be 
speculated that H2Bub1 as a highly dynamic transcription-specific chromatin 
modification may have a similar transcriptional function in human cells. 
5.2.2 JNK and nucleolar signaling are involved in reduction of H2Bub1 
Nucleoli are known to rapidly respond to environmental stress. Stress stimuli can 
activate members of the c-Jun NH2-terminal protein kinases (JNKs) that balance pro-
survival stimuli with opposing signals leading to apoptosis (Schreiber et al. 1995; 
Chen et al. 1996). JNK inhibits rRNA synthesis in response to stress by inactivating 
the transcription initiation factor TIF-IA which is required for RNAPI-dependent 
transcription (Bodem et al., 2000; Moorefield et al., 2000). In turn cells rapidly down-
regulate the synthesis of ribosomal RNA and release nucleolar proteins to carry out 
other regulatory functions (Mayer and Grummt, 2005). The results of our study 
showed a correlation between the loss of H2Bub1 upon Actinomycin D treatment and 
JNK activation, since both happened in the same range of concentration. What is 
more, pretreatment with a specific JNK inhibitor which partially rescued the 
Actinomycin D induced reduction of H2Bub1 levels providing circumstantial evidence 
for the dependence of the removal of this histone mark on JNK activity (Fig. 20). 
Based on these data one can speculate that the kinase activity of JNK can down-





5.2.3 Metabolic regulation of H2Bub1 levels 
In addition, we examined whether further kinases are involved in the stress-induced 
loss of H2Bub1. AMP-activated protein kinase (AMPK) regulates cellular metabolism 
in response to energy and was reported to activate transcription through direct 
association with chromatin (Bungard et al., 2010). Furthermore, implication of AMPK 
in activation of JNK was described (Schulz et al., 2008; Shirwany and Zou, 2010). 
AICAR is a known activator of AMPK and a previous study showed its ability to 
induce the phosphorylation of JNK, p38, MAPK, and ERK1/2 (Fisslthaler and 
Fleming, 2009). The remarkable reduction of global H2Bub1 levels upon AICAR 
treatment observed in the current study implies a potential role of AMPK in H2Bub1 
regulation. However, knockdown experiments using siRNAs directed against 
AMPK1, AMPK2 and the upstream AMPK-activating kinase LKB1 did not support 
the hypothesis of AMPK-involvement in the regulation of H2B monoubiquitination 
since little or no rescue of the reduced H2Bub1 level was detectable upon their 
depletion. Stress conditions deplete ATP stores and increase AMP content in cells 
(Hardie et al., 1999). AMPK recognizes changes in the AMP/ATP ratio by binding in a 
competitive manner (Xiao et al., 2007). Thus, increases in the concentration of AMP 
activate AMPK. Recent findings imply that only a small fraction of the total amount of 
cellular AMPK is amenable to AMP activation, suggesting that additional regulatory 
interactions, such as compartmentalization or covalent modifications (e.g. 
phosphorylation), are also involved in this binding process (Bungard et al., 2010). 
These data suggest that the loss of H2Bub1 protein level upon treatment of different 
stress-inducing factors might be less a consequence of activation of AMPK level but 
more due to changes in AMP/ATP ratio and metabolism itself. A further support for 
the involvement of metabolism in the regulation of H2Bub1 levels is the remarkable 
depletion of cellular ATP upon treatment with the glycolysis blocker 2-Deoxy-D-
Glucose (2-DG) which also results in decreased H2Bub1 levels. Metabolic 
reprogramming is associated with tumorigenesis and glucose can induce H2B 





5.3 Activation of a cellular deubiquitinating enzyme reduces 
H2Bub1 levels 
H2B monoubiquitination is a highly dynamic process and its level is not only 
regulated by addition, but also by active removal of the ubiquitin residue from the 
chromatin. According to our data the loss of H2Bub1 happens very quick which 
cannot be explained by decreased RNF20 and RNF40 levels alone. We 
hypothesized the activity of deubiquitinating enzymes (DUBs) as a responsible 
mechanism for the rapid removal of H2B monoubiquitination. Indeed, we 
demonstrated an increased deubiquitinating activity in Doxorubicin and AICAR 
treated cells. In our studies, we could observe a rescue of the H2Bub1 levels in 
Western blot and mRNA gene expression of RNF20/RNF40 target genes upon 
USP22 and ATXN7L3 depletion. 
In mammalian cells the DUB module for H2Bub1 is incorporated into the large Spt-
Ada-Gcn5-Acetyltransferase (SAGA) complex. USP22 is the deubiquitinating 
component of SAGA and was shown to deubiquitinate H2B in vitro (Zhao et al., 
2008). USP22 interacts with the DUBm subunits ATXN7, ATXN7L3, and ENY2. Our 
results allowed us to conclude that USP22 is at least partially responsible for the 
stress-induced deubiquitination. However, knockdown of core SAGA DUBm 
components like ATXN7L3 led to a more significant increase in H2Bub1 (Lang et al., 
2011). 
Thus, possible phosphorylation activity of JNK or different kinases on USP22 may 
modify the affinity of the USP22 zinc-finger domain to certain interaction partners like 
ATXN7L3, ENY2 or ATXN7. The release of the complete DUB module from the core 
SAGA complex may influence the activity of USP22 independent of the rest of the 
SAGA complex. This hypothesis is consistent with the observation that knockdown of 
GCN5, a core component of SAGA, did not affect H2Bub1 levels. The USP22 
knockdown led to a partial rescue of H2Bub1 upon stress-conditions, suggesting that 
other ubiquitin hydrolases may also perform deubiquitination of H2Bub1 in addition to 
USP22. Additional USPs, for example USP27X and USP51 share sequence 




As previously mentioned the proteins involved in the regulation of H2Bub1 levels are 
often misexpressed in cancers. Considering H2Bub1 as a tumor suppressor allows 
utilizing its regulators as potential therapeutic targets. Changes in the expression or 
activity of the ubiquitin conjugating enzyme UBE2A, the ubiquitin ligases RNF20 or 
RNF40 or the deubiquitinase USP22 as well as other subunits of the SAGA DUB 
module could all potentially play a role during tumorigenesis. USP22 was also 
discovered as a component of a so-called “death from cancer” 11- gene signature, a 
specific transcriptional profile of tumor cells containing genes whose expression is 
associated with poor clinical prognosis of cancer patients (Glinsky, 2005). Thus 
aberrant expression of USP22 can promote cancer (Liu et al., 2010, 2011; Zhang et 
al., 2011).  
Since our studies revealed a loss of H2Bub1 during tumor progression and 
metastasis we speculate decreased cellular differentiation and reversion to a stem 
cell-like phenotype. This hypothesis is supported by the correlation of USP22 mRNA 
levels with an undifferentiated stem-like phenotype in multiple types of cancer 
(Glinsky, 2005). Thus, multiple mechanisms which diminish H2B monoubiquitination 
such as decreased RNF20 or RNF40 expression or increased USP22 expression 
may similarly lead to a loss of H2Bub1 and reversion to a stem cell-like phenotype. 
Based on these data one could speculate that H2Bub1 and its upstream regulatory 
factors may have tumor and stage-dependent functions. An active suppression of 
H2Bub1 accumulation can be suggested, since several tumor types showed 
overexpressed USP22 (Glinsky, 2005) or hypermethylation of the RNF20 promoter 
(Shema et al., 2008). Additional ChIP and ChIP-seq studies to analyze H2Bub1, 
RNF20/RNF40, USP22 and ATXN7L3 occupancies and their correlation to global 
gene expression in malignant compared to normal cells may help to determine which 
benefit H2Bub1 depletion might have. 
Our group recently showed that H2Bub1 regulates differentiation of human 
mesenchymal stem cells (hMSCs) (Karpiuk et al., 2012). The presence of H2Bub1 is 
required for the resolution of bivalency on differentiation-regulated genes. This study 
identified a correlation between decreased differentiation and low H2Bub1 levels. In 




regulator of stem cell differentiation and suggest the importance of dynamic changes 
in H2Bub1 patterns in ESC (embryonic stem cell) differentiation (Fuchs et al., 2012). 
In addition to USP22, USP44 was recently reported as an H2B deubiquitinase which 
is highly expressed and maintains low levels of this modification in ES cells (Fuchs et 
al., 2012; Zhang et al., 2012). These two DUBs share a similar domain organization 
with a ZnF-UBP domain which was found in a subclass of 10 human USPs and plays 
an important role in the regulation of their enzymatic activity. It was shown that the 
ZnF-UBP domain of USP22 mediates interactions with other SAGA DUBm subunits 
and is therefore required for USP22 activation (Lang et al., 2011). Bioinformatic 
analyses predict that the ZnF-UBP from USP44 might be an ubiquitin-binding domain 
(Bonnet et al., 2008). It can be speculated that this enzyme acts as a sensor of free 
ubiquitin since it might be activated through the binding of free ubiquitin. Overall, it 
can be expected that besides SAGA that appears as the major H2B deubiquitination 
complex on mammals, other DUBs such as USP3, which is the closest homolog of 
yeast Ubp8 (Nicassio et al., 2007) or USP7 that was described to deubiquitinate H2B 
in Drosophila and in human cells (van der Knaap et al., 2005, 2010) will have specific 
effects in given cell types. 
  
5.4 H2Bub1 as a therapeutic target in cancer 
Given the function of H2B monoubiquitination in diverse nuclear processes including 
transcription and DNA repair, this pathway may be viable for therapeutic treatment. 
As it was demonstrated in the current study changes in H2Bub1 levels play a role in 
cancer. In order to investigate the potential role for H2Bub1 as a target for cancer 
therapy, it is important to determine levels of H2Bub1 in patient tumors and check for 
correlation with other clinical parameters especially patient outcome and therapeutic 
responsiveness as well as receptor status in breast cancer, e.g. HER2, estrogen 
receptor and progesterone receptor. 
Down-regulation of H2Bub1 during malignancy is in concordance with the “de-
differentiation” model. For patients with USP22-overexpressing tumors, treatment 




be used to reinstate H2Bub1. As a proof of principle, specific DUB inhibitors have 
already been developed for USP7 and USP8 (Colland, 2010). Treatments with these 
small-molecule inhibitors might restore a more differentiated cellular phenotype and 
thereby decrease cell proliferation thus provide a new tool for targeted therapy. 
Recent investigation identified a Polycomb signature as a key regulator of a stem 
cell-like transcriptional profile (Lahad et al., 2005; Ramalho-Santos et al., 2002). Two 
members of the stem cell signature belong to the Polycomb group of genes (Zhang et 
al., 2008a). BMI-1 catalyzes ubiquitination of histones and is essential for the function 
of Polycomb (Ben-Saadon et al., 2006). A proposed model is the importance of 
simultaneous induction of Polycomb ubiquitin ligases and USP22 during cancer 
progression. This model is supported by the requirement of USP22 for Myc and the 
potential contribution of BMI-1 with Myc during transformation (Zhang et al., 2008a). 
Thus, these findings suggest that overexpressed USP22 in cancer cells may activate 
the BMI-1 dependent pathway to induce stem cell-like characteristics like therapy 
resistance and increased metastasis (Xu et al., 2012). 
RING-ligases are difficult to target with chemical inhibitors, but recent success in the 
development of specific inhibitors of the E3 ligase activity MDM2 (murine double 
minute 2) and the MDM2-p53 interaction (Vassilev et al., 2004; Yang et al., 2005a) 
indicate the possibility of targets for other E2 and E3 ligases, including H2B 
monoubiquitination. The tumor suppressor p53 is negatively regulated by MDM2 
(Iwakuma and Lozano, 2003). Nutlin (for Nutley inhibitor) is able to bind to a 
hydrophobic pocket of the MDM2 protein, can impair the interaction of p53 and 
MDM2 and thus the ubiquitination and subsequent degradation of p53 by MDM2 
(Kussie et al., 1996; Vassilev et al., 2004). The RING ligases RNF20 and RNF40 
form an obligate heterodimer via multiple coiled-coil domains in their amino-terminal 
potions (Kim et al., 2009). Disruption of any of these motifs prevents dimerization and 
H2B monoubiquitination. The coiled-coil domain could therefore serve as a potential 
interaction surface for inhibitor design. Agents that impede the dimerization of RNF20 
and RNF40 via their coiled-coil domains might function to disrupt the whole complex 





Tumors of an earlier stage, which still exhibit significant levels of H2Bub1 may benefit 
from CDK9 inhibitors, since H2Bub1 can be decreased upon treatment (Minsky et al., 
2008; Pirngruber et al., 2009a, 2009b). The usage of specific CDK9 inhibitors, like 
flavopiridol showed just poor therapeutic potential but strengthened the efficiency of 
DNA damaging agents (Hara et al., 2008; Mason et al., 2004; Motwani et al., 2001). 
A possible explanation why loss of H2Bub1 could be a benefit in this case is the 
connection to DNA damging, since loss of H2Bub1 could predict increased sensitivity 
of tumor cells to chemo- and radiotherapy by blocking H2Bub1-dependent DNA 
repair processes. H2Bub1 negative tumors might show higher sensitivity to irradiation 
than H2Bub1 positive tumors. In addition, based on the findings in ES cells, an 
increase in H2Bub1 is required for differentiation as already mentioned above. On 
the other hand tumors with low H2Bub1 levels should be controlled since it can lead 
to even greater decrease of H2Bub1 and thus increased malignant transformation. In 
addition, bromodomain-containing protein BRD4 which recruits CDK9 to transcribed 
genes (Jang et al., 2005; Yang et al., 2005b), could be another interesting target. 
Further, several specific small molecule inhibitors of CDK9 were already described as 
anticancer agents (Dai and Grant, 2004). Thus, different types of malignancies 
should be examined to shed more light into the role of H2Bub1 and its upstream 
regulatory pathway components. 
Despite the fact that most studies indicate H2Bub1 and its ubiquitin ligases as tumor 
suppressors, a few data show a potential tumor promoting effect (Blank et al., 2012; 
Jaaskelainen et al., 2012; Liu et al., 2009). These effects could be explained by 
tumor-stage dependency. Particularly, H2Bub1 may play a role in suppression of 
metastasis and cancer stem cell phenotypes. A confirmation of this suggestion 
comes from the data of the present study where RNF20 and RNF40 knockdown 
decrease cell proliferation but increase cell migration. Further studies supported 
these findings and additionally showed an increased in in vivo tumor load (Shema et 
al., 2008). Again this explanation is in agreement with our data showing the loss of 
H2Bub1 during tumor progression in colon cancer samples and the observation of 
detectable H2Bub1 levels in early stage tumors and the absence in malignant and 




USP22 correlates with poor prognosis and a stem cell gene expression signature 
(Glinsky et al., 2005). 
Altogether, H2Bub1 can be used as an important marker of differentiated, non-
transformed tissue and reduced H2Bub1 levels can possibly be used as a potential 
diagnostic tool or target for epigenetic-based therapies of cancer. The results 
presented here provide new insights into the role and regulation of H2B 
monoubiquitination and reveal a strong rationale for further pursuing subsequent 
genome- and transcriptome-wide analyses, in vivo mouse tumor model experiments 
and immunohistochemical studies with larger patient cohorts with follow-up data. 
Together these results will help establish the role of H2Bub1 in tumorigenesis, tumor 
progression and therapeutic responsiveness.   
 
5.5 Genome-wide distribution of H2Bub1  
As it was demonstrated in this study, treatment with stress-inducing factors led to a 
decrease in global H2Bub1 levels. Our ChIP-seq data confirmed the genome-wide 
increase in the gene transcribed region which is consistent with the increase of global 
H2Bub1 levels observed by Western blotting and former ChIP experiments. An 
accumulation of H2Bub1 on RNF20/RNF40 regulated genes would likely account for 
the observed increase of the H2Bub1 level. H2Bub1 was shown to be associated 
with the transcribed region of active genes (Minsky et al., 2008). A key issue that 
remains to be elucidated is whether H2Bub1 in the transcribed region has a direct 
function in transcription elongation. If H2Bub1 facilitates the elongation by RNAPII, a 
global defect in gene expression would be expected in cells impaired for H2B 
ubiquitination. However, in contrast to the distribution of H2Bub1 on most active 
genes, suppression of H2B ubiquitination appears to have a mild effect on gene 
expression as only a small subset of genes had an altered expression after depletion 
of the H2B ubiquitination enzymes in human cells. This suggests that instead of 
directly facilitating transcriptional elongation, H2Bub1 that is deposited along with 
elongating RNAPII could have functions independent of the transcription elongation 
itself. Since our data demonstrated that H2Bub1 levels are high across the body of 




potentially explain differential regulation of genes. The analysis of the genome-wide 
averages of H2Bub1 in control compared to ATXN7L3 depleted cells performed in 
this study demonstrated that average H2Bub1 might not correlate with gene 
expression but that the deubiquitination does correlate with gene activity.  
A recent study revealed that deletion of CHD1, a chromatin remodeler required for 
maintaining high H2Bub1 levels resulted in a decrease in global H2Bub1 whereas 
both H3K4 and H3K79 trimethylation were not affected. Thus, CHD1 positively 
regulates gene expression through promoting nucleosome reassembly coupled with 
H2B monoubiquitination (Lee et al., 2012). Furthermore, H2Bub1 could be involved in 
transcription of micro-RNAs (miRNAs) or long non-coding RNAs (lncRNAs) which 
have shown to be recruited for differentiation (Crippa et al., 2012; Dong et al., 2012; 
van Leeuwen and Mikkers, 2010). To determine the effect of the loss of ATXN7L3 on 
overall gene expression and to correlate changes in RNA levels with changes in 
H2Bub1 enrichment additional RNA-seq analyses should be performed. 
Our results obtained in MCF10A cells indicate that the SAGA DUBm has a much 
more widespread activity on H2Bub1 than previously anticipated. Indeed, the 
increase in H2Bub1 levels upon ATXN7L3 knockdown in the transcribed region of 
highly expressed genes seems to be widespread indicating that SAGA is likely 
recruited to all these genes and acts throughout the gene bodies. The role of SAGA 
has been extensively studied in yeast where it is essential for GAL1 transcription via 
binding to the promoter prior to recruitment of RNAPII and pre-initiation complex 
formation (Bhaumik and Green, 2001; Bryant and Ptashne, 2003; Larschan and 
Winston, 2001). Furthermore, SAGA binds to promoters of many different genes in 
several metazoan species (Lang et al., 2011; Nagy et al., 2009; Weake et al., 2011). 
In addition, it was shown that SAGA subunits, including ATXN7L3 localize to gene 
promoters linked to stress response, transcriptional regulation and replication (Lang 
et al., 2011; Nagy et al., 2009; Vermeulen et al., 2010). Since all these studies 
showed that SAGA is required to be recruited to gene promoters to activate 
transcription we anticipate that ATXN7L3 may also be localized near the 5’ end of 
these genes. This is supported by our results which showed that the increase of 
H2Bub1 occurs primarily around the 5’ end of genes. However, studies of the 




certain regions of the genes could shed important insight into the role of the SAGA 
DUBm complex in controlling dynamic H2B monoubiquitination. 
Taken into account that dynamic changes of H2Bub1 levels upon stress induction do 
correlate to gene expression, it may be possible to utilize this mechanism to affect 
gene expression levels. Recently our group could show that proteasome inhibition 
caused a rapid loss of H2Bub1 and decreased chromatin dynamics (Prenzel et al., 
2011). Based on the results represented here proteasome inhibition via MG132 or 
Bortezomib may specifically decrease H2Bub1 on the most highly transcribed genes.  
All together our data reveal a tight regulation for the setting and the removal of 
H2Bub1 that appears to be extremely dynamic. Further analysis of our ChIP-seq data 
as well as ChIP-seq against ATXN7L3 to determine binding profiles investigating the 
genome-wide co-occupancy of H2Bub1 and ATXN7L3 might shed further light on this 
question. Furthermore RNA-seq analyses upon ATXN7L3 knockdown will help 




Collectively, this study reveals important insight into the complex mechanism of the 
regulation of histone H2B monoubiquitination. Our data demonstrate the validity of 
H2Bub1 and its ubiquitin ligases RNF20 and RNF40 as potential tumor suppressors. 
We could further show a stress-induced loss of H2Bub1 and a rescue of the global 
H2Bub1 levels through knockdown of a deubiquitinating enzyme or subunits which 
interact with it. To shed some more light on the proposed mechanisms of H2Bub1 
regulation, further careful and extensive study of this process is required for the 
development of solid knowledge of stress-induced H2B deubiquitination and the role 
of H2B monoubiquitination during tumorigenesis and metastasis. Filling these gaps 
will provide an advance in understanding the role of H2Bub1 as well as the potential 
of epigenetic-based therapies for cancer.  
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